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Abstract: Electrochemical enzyme-linked immunosorbent assay (ELISA)-based immunoassays for
cancer biomarker detection have recently attracted much interest owing to their higher sensitivity,
amplification of signal, ease of handling, potential for automation and combination with miniaturized
analytical systems, low cost and comparative simplicity for mass production. Their developments
have considerably improved the sensitivity required for detection of low concentrations of cancer
biomarkers present in bodily fluids in the early stages of the disease. Recently, various attempts
have been made in their development and several methods and processes have been described
for their development, amplification strategies and testing. The present review mainly focuses on
the development of ELISA-based electrochemical immunosensors that may be utilized for cancer
diagnosis, prognosis and therapy monitoring. Various fabrication methods and signal enhancement
strategies utilized during the last few years for the development of ELISA-based electrochemical
immunosensors are described.
Keywords: electrochemical ELISA; serum; immunoassay; antibodies; cancer detection
1. Introduction
Cancer is one of the major causes of mortality in the world. Many factors, including exposure to
cancer-causing reagents, exposure to radiation, infections, genetic modifications, etc., can disrupt the
cells and result in their modification and proliferation causing the generation of cancer in different parts
of the body. Its diagnosis based on visual symptoms is not recommended as such symptoms appear in
later stages of cancer, when there are no efficient therapies. Thus, it is advised to diagnose it in early
stages, when useful treatment is possible, in order to achieve longer survival of cancer patients [1].
To achieve early stage diagnosis researchers have proposed the use of proteins and oligonucleotides
released in the body during the early stages of cancer and not present in the same concentrations in
healthy individuals. Such molecules are known as biomarkers and different types of cancers release
different biomarkers, whose detection and estimation can provide very valuable information regarding
cancer type and its stage. Thus, it is very important to develop systems, which are simple, low cost
and can provide sensitive and specific estimation of such biomarkers [2]. Further, taking into account
population and cancer stage variability as well as low levels of biomarkers in early stages in cancer, it
is recommended to identify and test panels of multiple biomarkers for better accuracy in diagnosis.
Also, it is desired to detect these biomarkers in a non-invasive or minimally invasive manner with
high selectivity, sensitively and free from false positives and false negatives. Commonly employed
methods of cancer detection such as enzyme-linked immunosorbent assay (ELISA), western blotting,
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optical, electrochemical, fluorescence or radio immunosensor-based systems also utilize biomarkers
for analysis and their estimated levels are related to cancer stage and inform cancer therapy [3,4].
With advances in cancer biology and immunology, researchers have discovered various potential
biomarkers specific to particular cancers and related to the bio-mechanism of cancer cells.
Till date, mainly optical sandwich ELISA-based detection of biomolecules is employed in clinical
practice and commonly considered as the gold standard method. These assays use antibodies for
specific identification and quantification of the desired antigen/biomarker in a process known as
immunoassay; sensors used for these assays are known as immunosensors [5,6]. In the medical
diagnostics industry, traditional optical ELISA is usually carried out in 96 well plates. Suppliers
provide kits of reagents and 96 well plates for desired analytes testing and estimation. In such
kits, 96 well plates generally come with a primary antibody coated into the wells of the plate via
physical adsorption followed by blocking to prevent non-specific binding. The kits also provide
operating procedures. In brief, an antigen sample is first incubated with primary antibodies in the
well for the required time to make antibody–antigen complex. After incubation, plate is usually
washed with wash buffer provided by the kit provider. After washing antigen-antibody complex
is incubated with enzyme tagged detection antibody to form antibody-antigen-antibody sandwich.
After incubating for the desired time, followed by washing with wash buffer, the complex is incubated
with enzyme substrate and indicator dye. During incubation, the enzymatic reaction results in change
of color for indicator dye, which on measurement using optical reader provide the absorbance value.
Absorbance value on comparison with standard solution calibration provide the analyte concentration.
The whole testing procedure is quite lengthy and often requires an expensive optical reader for
analyte estimation. However, the use of a sandwich method provides amplified response and thus
results in better detection range. In brief, optical ELISA provides highly reproducible, sensitive and
specific, quantitative data that makes it an advantageous biotechnological tool in scientific research
and clinical diagnosis. However, optical ELISA suffers from tedious/laborious procedures, necessity
for centralized laboratory equipment, and a relatively high sample volume is required. Moreover, the
detection limit of conventional ELISA is barely less than the nanomolar concentration level, which is
inadequate to reach the clinical threshold of many protein biomarkers, especially in the early stage
of diseases.
Electrochemical assays have shown the promise to overcome these issues. Electrochemical
assay provides the advantage of easy procedure, portable instrumentation, low volume and
faster measurements. However, like for optical ELISA in 96 wells performing large multiplexing
simultaneously, not much success has been reported in electrochemical assays. Among electrochemical
assays, electrochemical ELISA has shown promise, as it combines the advantages of optical ELISA like
sensitive and specific, multiplexing, quantitative data with advantages of an electrochemical assay
like faster, lower sample volume, low cost instrumentation, etc. Thus, to shorten the time required
and to improve the response and characteristics of traditional optical ELISA, various researchers have
proposed newer technologies via development of improved sensor surfaces and detection probes.
Also, to reduce cost, easier testing and shorter measurement time, sandwich-based electrochemical
ELISAs have been proposed, which utilize the specificity of optical ELISA and advantages of
electrochemical measurements to achieve better response and characteristics for desired analyte
estimation. In contrast to optical ELISA, electrochemical ELISA uses a potentiostat/galvanostat for
signal measurement in research laboratories. Though at present there are not many commercial
electrochemical ELISA based immunosensors, the required instrumentation is available and as
such there is huge potential for such sensors and their commercialization. Furthermore, the ease
of miniaturization of required electronics has potential for smaller, simpler and low cost systems
for such measurement. In brief, it has been suggested that, to overcome limitations of optical
ELISA, whilst maintaining the advantages of traditional assays, electrochemical immunosensors
may provide a workable alternative [7–9]. Electrochemical immunosensors utilizing potential, current
or impedance based techniques may provide the desired sensitivity in very low volume samples
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at faster rate of analysis along with ease of fabrication, measurement and mass production at low
cost [9–12]. Keeping these advantages in mind, researchers have recently focused on the development
of electrochemical ELISA-based systems to combine the advantages of sandwich assays used in
optical ELISA and electrochemical detection [13]. Electrochemical ELISA enjoys the specificity
and signal amplification obtained by the use of synchronized binding of the recognition molecule
and detection molecule, along with high sensitivity, low detection limit, easy handling and easy
detection in miniaturized format provided by electrochemical detection. With evolving material
and surface chemistries along with advancing bio- and nano-technologies, electrochemical ELISA
based immunosensors have been gaining much interest and promising to replace traditionally used
optical ELISA to achieve faster, more sensitive, cheaper and reliable detection of cancer biomarkers
in for early stage diagnosis [14,15]. The present review describes various new ways reported by
researchers in the last 3 to 4 years for developing and improving sandwich-based electrochemical
ELISA for cancer biomarker detection. Authors in many of these reports validated their approaches
in spiked/real samples in vitro. There is no information regarding commercialization of any of these
sensors at present, however these reports may pave way for better and faster diagnostic of cancer at
earlier stages in the near future. Also, there are various useful reviews that have been published for
electrochemical immunosensor-based cancer biomarker detection in past using nanoelectrodes, arrays
and microfluidics [16–18]. Thus, in the future, combining the new advancements in sensor surfaces
and detection probes described here with nanoelectrode arrays or microfluidics will further enhance
the chances of achieving better sensitivity and detection limits required for early stage measurements
of biomarkers.
1.1. Electrochemical Sandwich ELISA
Electrochemical sandwich ELISA is a branch of electrochemical immunoassays where the
recognition of a desired target is done using a traditional sandwich assay and detection is achieved
using an electrochemical method [19–21]. These immunoassays mainly involve three layers:
immobilized biorecognition molecule (probe), target analyte that binds specifically to the biorecognition
molecule, followed by binding of a secondary recognition molecule with an electrochemically active
signal tag. For signal measuring, the electrochemical signal tag either provides the signal directly or a
reaction with a substrate is induced afterwards [22,23]. The generated signal is directly proportional
to the analyte concentration. This type of sensing involving sandwiching of target analyte between
two highly specific capturing and recognition molecules, provides a high level of sensitivity and
specificity and makes it suitable for early stage detection of cancer biomarkers [14]. For capturing and
recognition molecules one can utilize combinations of suitable molecules ranging from antibodies,
aptamers, DNA base sequences, bacteriophages, peptide nucleic acid sequences, etc. [2]. And for
sensitive detection researchers have utilized various tags involving redox enzymes, metallic particles,
quantum dots, etc., which they have used directly or in combination with another matrix for enhanced
loading [6,14,24,25]. Other than these, the activity and recognition ability of developed sensors also
depend on how and where the capturing molecule is immobilized and how well it can interact with
the target analyte. Thus, innovative methods for binding of capturing agents on the desired surface
(hereafter referred to as matrix, to reflect the modification of the electrode with different molecular
and polymeric layers) for sensitive analyte capture are required for developing novel immunosensors.
Further, the selection and development of a suitable matrix for binding of capturing agent is crucial
to achieve optimum response from the assay [5]. Thus, for development of novel electrochemical
ELISA-based immunosensors, research groups are working on finding newer and better matrices along
with novel methods of binding capturing agents on the desired matrices and have proposed numerous
approaches for higher binding of capturing molecules with better retained activity. Researchers have
also proposed new and innovative methodologies to amplify the signal generated by binding events of
target and recognition molecule. This review will focus mainly on the recent advances made by various
groups in methods of making such electrochemical ELISA-based immunosensors for cancer biomarkers
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detection using innovative surface chemistries and materials along with their measuring methodology
and response to analyte. For development of enhancement strategies, researchers have utilized various
biomarkers such as CEA, AFP, PSA HER2, SCC, CA 125, CA 19-9, etc. Among these biomarkers CEA,
AFP and PSA have gained much attention as model biomarkers for developing enhancement strategies.
In a normal person, the cut-off concentration for CEA, AFP, CA 125 and PSA are found to be 3 ng/mL,
10 ng/mL, 46 U/mL and 4 ng/mL, respectively, and higher concentrations are oftern related to cancer
stages. Immunosensors and enhancement strategies are normally investigated keeping these ranges
in mind; the immunosensor is useful if it can detect concentrations lower than the cut off limit.
1.2. General Mechanism of Enhancement Strategies
In sandwich-based electrochemical ELISA, signals can be enhanced by increasing the capturing
efficiency via the use of better antibodies or by their higher loading on sensor surface. Signals can also
be enhanced via detection probes containing a larger number of detection tags. Thus, sensor surfaces
where capture antibodies are immobilized and detection probes containing detection antibodies and
tags play the main roles in achieving enhancement in signal. In general, enhancement in response has
been achieved using modified sensor surfaces or improved detection probes. Using modified surfaces,
researchers have tried to increase the surface area via use of nanomaterials and their composites, thus
resulting in higher loading of antibodies. Also attempts were made to immobilize capturing antibodies
in the desired orientation for enhance capturing efficiency, thus resulting in signal enhancement.
In use of improved detection probes, researchers have utilized high surface area of nanomaterials
and composites for loading of larger number of detection antibodies with tags or catalytic materials.
On interaction of detection probe with antibody-antigen complex, one of the detection probe binds
to antigen but many more are also available for further catalytic reaction of the detection substrate.
In case of enzymatic tags, a larger number of tags results in larger conversion of specific analyte,
thus resulting in larger quantity of detection molecules. Also, in the case of nanomaterial based
catalytic tags on detection probe, large number of tags result in larger catalytic conversion of target
substrate, thus resulting in higher response. Figure 1 shows the general detection strategy for optical
and electrochemical ELISA.
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2. Matrix Selection, Modification and Development of Immunosensors
The development and properly working immunosensors involves the selection and preparation
of a binding matrix followed by immobilization of capturing molecule on the surface of the electrode.
The matrix for an electrochemical sensor can comprise monolayers, polymers, carbon based materials,
nanomaterials or their composites [13,14,25,26]. Most commonly utilized capturing molecules include
antibodies, antibody fragments, DNA/RNA aptamers and peptide aptamers, which are immobilized
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directly on a conducting/semiconducting electrode surface or on a pre-modified electrode surface
via physical, entrapment or covalent methods [27]. Other than these, researchers have also employed
oriented biomolecular immobilization approaches either by using engineered capturing molecules, or
by using molecules such as protein A, which allows the binding of antibodies in an ‘upright’ position
for best activity. In any type of chosen method for binding of capturing molecule, the main emphasis
during immobilization is to retain or enhance the capturing molecule activity and stability. Further,
binding can also be characterized based on the chosen matrix [27].
In recent years, carbon-based matrices involving graphene oxide (GO) [28], reduced graphene
oxide (rGO) [29], graphene sheets [30–32], carbon nanotubes [24,33] and their composites with
nanoparticles [33–35], polymers [36], etc., have recently attracted much attention owing to their
high conductivity, large surface area, and stability. In most of the cases, blocking of free surface areas
on the sensor chip after capture molecule binding was achieved using BSA solution incubation.
In one example, Gao et al. utilized graphite to prepare GO, which was then reduced and nitrogen
doped before coating on a glassy carbon electrode (GCE) for antibody binding via glutaraldehyde
chemistry [28]. They further showed the use of β-cyclodextrin-graphene (β-CD-GR) for GCE coating
and binding of capture antibody (Ab1)-adamantine (ADA) via physical adsorption [37]. A few
other researchers have also utilized the CD-GS based matrix for immunosensor development [38,39].
Li et al. described another approach where single walled carbon nanotubes (SWCNTs) were mixed
with L-cysteine modified chitosan (CS) to obtained thiol terminated CSSH-SWCNTs, which can be
immobilized on gold surfaces from one side and can be employed for gold nanoparticles (AuNPs)
binding on other side for larger surface area and Ab1 binding [40]. Similar to this, Wang et al. reported
the use of AuNPs decorated mercapto-functionalized graphene sheets (Au@SH-GS) as matrix on GCE
for Ab1 binding [41].
In composites with polymers, Feng et al. described use of hierarchically aloe-like gold
microstructures (HAG)/polyaniline (PANI)/rGO, where PANI and HAG were electrochemically
deposited on rGO coated GCE [36]. In other study, Kavosi et al. described the development of
immunosensor using gold nanoparticles/polyamidoamine dendrimers (AuNPs/PAMAM dendrimer)
loaded MWCNTS/CH/ionic liquid (IL) nanocomposite onto GCE surface [42]. Figure 2 shows the
schematic for the sensor development and detection procedure. AuNPs-IL-rGO nanocomposite
has also been utilized for immunosensor development [43,44]. Other than these, many
other composites like gold-(3-aminopropyl)triethoxysilane-GS (Au@APTES-GS) [45], Au-GR [46],
AuNPs/thionine(Thi)-CNTs [47], etc. have been utilized and shown to provide novel matrices for
immunosensor development.
Other than graphene or CNTs, gold has been used as matrix independently or with many other
matrices in composite form for biofunctionalization. Use of such nano and hybrid materials, whose
properties can be controlled and tailored in a desired manner have provided a viable opportunity
to develop clinically relevant immunoassays in the biomedical arena. Some examples include
use of electrochemically deposited AuNPs [48–51], AuNPs-Chitosan [52–54], nanoporous gold
(NPG) prepared by acid based removal of silver from silver gold alloy [55], MoS2-Au hybrids [56],
Au-multifunctional mesoporous silica (MCM-41) [57], poly(o-phenylenediamine)-AuNPs [58], etc.
Other than these nanomaterials and composites, other materials such as polymers, magnetic
materials, electrodeposited films and monolayers has also been utilized for immunosensor
development. Wang et al. described the use of Ab1 tagged Dynabeads conjugates [59], while Zhou et al.
described CD coated GCE electrode for immunosensor development [60]. Further, PAMAM modified
GCE [61], cysteine monolayer on gold [62], etc. have also been utilized for advanced immunosensor
development. Table 1 summarizes the various approaches used for immunosensor development.
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Figure 2. Illustration of the stepwise process for PSA immunosensor fabrication. Briefly, to prepare
sensor electrode, physical mixture of MWCNTs and IL was coated onto GCE which was then modified
with PAMAM decorated gold nanoparticles via phthaloyl chloride chemistry. Phthaloyl chloride
chemistry was further utilized for thionine and anti-PSA immobilization. Reproduced with permission
from [42].
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Table 1. Various immunosensors and their preparation conditions.
Immunosensor Components Preparation Conditions BindingTechnique Target Ref.
Ab1/GS/SPCE GS Acid treatment of graphite flakes EDC/NHS(covalent)
CEA, CA125,
CA153 [30]
Ab1/N-GS/GCE N-GS
GO prepared from acid treatment of
graphite and then reduced with DMF at
153 ◦C to get N-GS
glutaraldehyde
(covalent) SCCA [28]
Ab1-ADA/CD-GN/GCE
Ab1-ADA EDC/NHS chemistry
physical CEA [37]CD-GN
GO prepared from acid treatment of
graphite and then reduced with hydrazine
in presence of ammonia and β-CD at 60 ◦C
to get CD-GN
Ab1/MWCNTs/GCE MWCNT-COOH Acid treatment of MWCNTs EDC/NHS(covalent) AFP [33]
Ab1/CD-GS/GCE CD-GS
GO prepared from acid treatment of
graphite and then reduced with hydrazine
in presence of ammonia and β-CD at
180 ◦C to get CD-GS
physical AFP [38]
Ab1-GS/GCE GS
GO prepared from acid treatment of
graphite flakes and then reduced with
hydrazine at 100 ◦C to get GS
EDC/NHS
(covalent) CA 15-3 [31]
Ab1-ADA/CD-GS/GCE
Ab1-ADA EDC/NHS chemistry
EDC/NHS
(covalent) AFP [39]CD-GS
GO prepared from acid treatment of
graphite and then reduced with hydrazine
hydrate in presence of ammonia and β-CD
at 60 ◦C to get CD-GS
Ab1-PA/AuNP/
CSSH-SWCNTs/Au
AuNPs Sodium citrate based reduction at 100 ◦C PA-antibody
interaction
AFP [40]
CSSH EDC/NHS chemistry
anti-HER2 Nb/SPE COOH-SPE Acid treatment at 1.6 V EDC/NHS(covalent) HER2 [63]
Ab1/GS-Thi/GCE GS-Thi Thi adsorption on GS EDC/NHS(covalent) AFP [64]
Ab1/IL-rGO/GCE IL-rGO treating GO with IL-NH2 in KOH at 80 ◦C
glutaraldehyde
(covalent) CEA, AFP [29]
Ab1/N-GS-CH/GCE N-GS-CH
GO prepared from acid treatment of
graphite and then undergo thermal
annealing in ammonia to get N-GS which
was then mixed with CH to get N-GS-CH
glutaraldehyde
(covalent) SCC [65]
Ab1/rGO-TEPA/GCE rGO-TEPA rGO-TEPA EDC/NHS(covalent) CEA, SCCA [66]
Ab1/rGO-TEPA/GCE rGO-TEPA rGO-TEPA EDC/NHS(covalent) CA72-4 [67]
Ab1-GS/GCE GS-COOH
GO prepared from acid treatment of
graphite and then undergo thermal
exfoliation in quartz tube at 1000 ◦C to get
GS which was then treated chloroacetic
acid in basic media to generate GS-COOH
EDC/NHS
(covalent) CA15-3 [32]
Ab1/MWCNTs/
DAH/GCE
MWCNT-COOH Nitric acid treatment of MWCNTs
EDC/NHS
(covalent) PSA [68]DAH
monolayer CV scans in 0.2 and 1.6 V at 20 mV/s
Ab1/CH/rGO/
SPC/whatman paper rGO
GO prepared from acid treatment of
graphite and reduced electrochemically at
−1.0 V CH coating
glutaraldehyde
(covalent)
AFP, CEA,
CA125, CA153 [69]
Ab1/nafion-AuNP-
DN-GR/GCE
GR
GO prepared from acid treatment of
graphite and reduced using NaBH4 at
85 ◦C physical CEA [34]
AuNPs Sodium citrate based reduction at 97 ◦C
Ab1/thionine/
AuNP-PMMA dendrimer/
CH-MWCNTs-IL/GCE
AuNP-PMMA
dendrimer
AuNPs prepared via citrate method were
mixed and incubated with thiol terminated
PAMAM prepared via treating
amine-terminated PAMAM dendrimer (G4)
with methyl mercaptoacetate at 50 ◦C
phthaloyl
chloride
(covalent)
PSA [42]
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Table 1. Cont.
Immunosensor Components Preparation Conditions BindingTechnique Target Ref.
Ab1-thionine/CH/
rGO/GCE rGO
GO prepared from acid treatment of
graphite and reduced electrochemically at
−1.0 V CH coating
glutaraldehyde
(covalent) PSA [70]
Ab1/Au@SH-GS/
GCE
AuNPs Sodium citrate based reduction inboiling condition
physical SCCA [41]
SH-GS
GO prepared from acid treatment of
graphite was treated with MPTES at 70 ◦C
followed by treating with hydrazine
hydrate at 95 ◦C to get SH-GS
Ab1/AuNPs-IL-rGO/
GCE
IL-rGO GO was mixed with IL-NH2 in KOH andreflux at 80 ◦C to get IL-rGO
physical AFP, CEA, PSA [43]
AuNPs-IL-rGO
IL-rGO mixed with HAuCl4 was reduced
using ascorbic acid to get
AuNPs-IL-rGO nanocomposite
Ab1/Au@APTES-GS/
GCE
APTES-GS
GO treated with APTES at 70 ◦C followed
by treating with hydrazine hydrate at 95 ◦C
to get APTES-GS
physical CEA [45]
AuNPs HAuCl4 reduction using NaBH4 in ice bath
Ab1/CH/
rGO/GCE rGO
GO prepared from acid treatment of
graphite and reduced electrochemically at
−1.0 V after CH coating
glutaraldehyde
(covalent) CEA [71]
Ab1/AuNPs-IL-rGO/
GCE
IL-rGO GO was mixed with IL-NH2 in KOH andreflux at 80 ◦C to get IL-rGO
physical CEA, AFP [44]
AuNPs HAuCl4 reduction using NaBH4 and/orsodium citrate
Ab1/Au-GR/GCE Au-GR Mix HAuCl4 with GO and perform 5 CVscan in −1.5 V to 0 V at 50 mV/s physical
AFP, CEA,
CA125, PSA [46]
Ab1/Au-PGO/GCE Au-PGO Treat GO, HAuCl4 and PEG mixture at180 ◦C physical CA19-9 [72]
Ab1/Au-Gra/GCE Au-Gra Treat GO-AA mixture with HAuCl4 atroom temperature physical AFP [73]
Ab1/AuNPs/
CH-Thi-CNTs/
GCE
AuNP Electrochemical deposition at −200 mV
physical CEA [47]
Thi-CNT Modify COOH-CNTs with thionine usingEDC/NHS chemistry
Ab1/GO-AuNP/GCE GOAuNP physical CEA [35]
Ab1/HAG/PANI/
rGO/GCE
HAG Electrochemically deposited at −200 mV physical CEA, AFP [36]
PANI Electro-polymerization at 0.75 V
Ab1/CH-AuNP/GCE CH-AuNPs NaBH4 based reduction ofCH-HAuCl4 solution
EDC/NHS
(covalent) CEA, AFP [52]
Ab1/NPG/GCE NPG Acid based removal of silver from silvergold alloy physical CA72-4 [55]
Ab1/AuNPs/GCE AuNPs Electrodeposited at −0.2V physical CEA, AFP [48]
Ab1/AuNPs/GCE AuNPs Electrodeposited at −0.2V physical AFP [49]
Ab1/AuNPs/GCE
AuNPs Sodium citrate based reduction inboiling condition physical AFP [50]
AuNPs/GCE Electrochemical deposition at 1.5 V
Ab1/CH-AuNP/GCE CH-AuNPs NaBH4 based reduction ofCH-HAuCl4 solution
Physical CEA, AFP [53]
Ab1/MoS2-Au/GCE MoS2-Au
Citrate based reduction of HAuCl4-MoS2
nano-sheets solution Physical CEA [56]
Ab1-TB/
Au@MCM-41/GCE
NH2-MCM-41 Treating MCM-41 with APTES at 70 ◦C physical AFP [57]
AuNPs HAuCl4 reduction using NaBH4 in ice bath
Ab1/CH-AuNPs/
GCE CH-AuNPs Refluxing CH-HAuCl4 solution for 1 h
glutaraldehyde
(covalent) CEA, AFP [54]
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Table 1. Cont.
Immunosensor Components Preparation Conditions BindingTechnique Target Ref.
Ab1-biotin/
streptavidin/
Au–Fe3O4@SiO2/
Au/magnet
Fe3O4
Treating FeCl2, FeCl3, and PEG 4000
mixture with NaOH at 80 ◦C
streptavidin-biotin
interaction
CA 19-9 [74]Fe3O4@SiO2
Treating PDDA-Fe3O4 solution pH 11
(using ammonia) with TEOS at
room temperature
Au–Fe3O4@SiO2
Treating PDDA-Fe3O4@SiO2 solution with
AuNPs solution
Ab1/PSS/
IL-rGO/GCE IL-rGO
GO was mixed with IL-NH2 in KOH and
treated at 80 ◦C electrostatic CEA, PSA, AFP [75]
aptamer/AuNP/
oPD/Au oPD/Au
Electropolymerized via CV scans in −0.5
and 0.8 V range at 50 mV/s physical MUC 1 [58]
Ab1/AuNPs/GCE AuNPs Electrodeposited at −0.2 V physical AFP [51]
Ab1/PANI/Au/paper
Au
Seed layer using AuNPs prepared via
NaBH4, citrate method;
Au layer using growth solution of HAuCl4
cetyltrimethyl ammonium chloride
glutaraldehyde
(covalent) CEA, AFP [76]
PANI 20 CV scans in −0.1 to 0.8 V rangeat 50 mV/s
Ab1/β-CD/GCE oxidize GCE 5 CV scans in H2SO4 solution in 0 to 2 V physical CEA [60]
Ab1/PAMAM/GCE PAMAM/GCE Using infrared light treatment EDC/NHS(covalent) PSA [61]
Ab1/cysteine /
Au cysteine /Au Self-assembled monolayer
EDC/NHS
(covalent) CEA [62]
PSA aptamer/
GDPTS/PDMS GDPTS/PDMS Self-assembled monolayer
epoxide
chemistry PSA [77]
Ab1/
Au@MWCNTs-SO3H/
GCE
MWCNTs-SO3H
Refluxing MWCNTs in H2SO4-HNO3 at
120 ◦C, 30 min physical PSA [78]
AuNPs Sodium citrate based reduction at 100
◦C
reflux
Ab1/PDA-rGO/GCE PDA-rGO Mixing dopamine with GO and stirring for24 h at 25 ◦C physical CEA [79]
Ab1/AuNPs/GCE AuNPs Electrodeposited at −0.2 V physical
CEA, NSE,
CA125,
Cyfra21–1,
SCCA
[80]
Ab1/MPA/Au MPA/Au Self-assembled monolayer EDC/NHS(covalent)
PSA, PSMA,
IL-6, PF-4 [81]
Ab1/MUDA-mercapto
ethanol/Au
MUDA-mercapto
ethanol Self-assembled monolayer
EDC/NHS
(covalent) PSA [82]
Ab1/PS physical PSA [83]
Ab1/3D-G-CH/GCE 3D-G
GO was first prepared from natural
graphite powder by Hummer’s method
followed by autoclaving at 180 ◦C to get
3D-G. Dried 3D-G was then mixed in
1% CS
glutaraldehyde
(covalent) CYFRA21-1 [84]
Ab1/polystyrene;
AgNP/SPCE AgNPs
Sodium citrate-based reduction of AgNO3
in boiling condition physical AFP [85]
antiHER2/
APTMS-Fe3O4/GCE
Fe3O4
Chemical co-precipitation from
FeCl3·6H2O and FeCl2·4H2O mix using
ammonia solution
glutaraldehyde
(covalent) HER2 [86]
Anti-CEA/LPA/Au NHS-LPA/Au Self-assembly covalent CEA [87]
Ab1-AuNPs/CHI/SPE AuNPs
Electrochemical reduction in 0.5 M H2SO4
via CV scans between −1.5 and 0.5 V at a
rate of 30 mV/s
physical PSA [88]
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BSA/anti-CEA/
AuNPs/GCE AuNPs
Electrodeposit deposition by cyclic
sweeping in the potential range of −0.5 to 0
V (vs. SCE) at 50 mV/s for 50 segments
physical CEA [89]
Ab1/Au@Th/GO/GCE Au@Th/GO
GO synthesized using modified Hummers’
method was mixed with Thi and HAuCl4
solution and stir
physical PSA [90]
Ab1/
Au@MWCNTs-SO3H/
GCE
AuNPs Citrate reduction of HAuCl4 solution;
physical PSA [78]Au@MW
CNT-SO3H
Physical adsorption of AuNPs on
MWCNTs-SO3H
Ab1/Au@MPTES-GS/
GCE
AuNPs Citrate reduction of HAuCl4 solution
physical AFP [91]
MPTES-GS
GO synthesized using modified Hummers’
method was treated with MPTES in ethanol
at 70 ◦C for 2 h followed by treatment with
hydrazine solution at 95 ◦C for 1.5 h
Ab1/AuNPs/
GCE AuNPs Electrochemical reduction at −0.2 V, 30 s physical CEA [92]
Ab1/β-CD/
MWCNT/GCE β-CD/MWCNTs Grind rMWCNTs and β-CD in ethanol physical CEA [93]
Ab1/
streptavidin-NG-CH/
GCE
NG-S
GO synthesized using modified Hummers’
method was refluxed with hydrazine at
100 ◦C, 24 h. Obtained rGO was then
mixed with pyrrole and treated with
ammonium peroxydisulphate. Obtained
PPY-rGO was heat treated till 600 ◦C, 2 h
Biotin-streptavidin [94]
Ab1/AuNPs/GCE AuNPs Electrochemical reduction at −0.2V, 30 s physical CEA [95]
Fe3O4@AuNPs-Ab1
Fe3O4
From ferrous complex via hydrothermal
method using H2O2 as oxidizer
physical AFP [96]
Fe3O4@AuNPs
Mixture of Fe3O4 NPs with PEG 20000 and
HAuCl4 was treated with hydroxylamine
hydrochloride
Ab1/Au/ZnO/
RGO/GCE Au/ZnO/RGO
GO synthesized using modified Hummers’
method was mixed with C12N3. Solution
was adjusted to pH 12 and mixed with
Zn(NO3)2 and HAuCl4 followed by
treatment with hydrazine at 105 ◦C, 5 h
physical AFP [97]
Ab1/CH/
CNT/SPE CH/CNT/SPE
Acid treated CNTs were mixed with nafion
117 and drop casted on SPE followed by
deposition of CH solution
glutaraldehyde
(covalent) PSA [98]
Ab1/AuNP/GCE AuNPs Electrochemical reduction at −0.2 V, 30 s physical SCCA [99]
Ab1/AuNP/GCE AuNPs Electrochemical reduction at −0.2 V, 30 s physical AFP [100]
Ab1-BSA/AuNP/
PANI/GCE
PANI/GCE Phytic acid doped polyaniline viaelectrochemical co-deposition at 0.8 V, 400 s
physical PSA [101]
AuNPs
Electrodeposit deposition by cyclic
sweeping in the potential range of −1 to
0.2 V at 50 mV/s, 10 cycles
Ab1/AuPd NCNs/
GCE AuPd NCNs
Add HAuCl4, H2PdCl4 and PVP
sequentially into NaOH solution
containing T7AA
physical CA 15-3 [102]
Ab1/Au@PDA/
GCE Au@PDA
Citrate reduced AuNPs were treated with
dopamine in tris buffer physical CEA [103]
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Ab1/Au@N-GQD/
GCE
N-GQD Dicyandiamide and CA solution wasautoclaved at 180◦C, 12 h
physical PSA [104]
Au@N-GQD
HAuCl4 was added to N-GQD, pH
adjusted to 10 using NaOH followed by
autoclaving at 160 ◦C, 6 h
Notes: β-CD: β-cyclodextrin; 3D-G: 3-dimensional graphene; AA: ascorbic acid; Ab1: capture antibody;
ADA-COOH: adamantine-1-carboxylic acid; AFP: α-fetoprotein; APTES: 3-aminopropyltriethoxysilane;
APTMS: 3-aminopropyltrimethoxysilane; CA: citric acid; CA 19-9: carbohydrate antigen 19-9; CA125: carbohydrate
antigen 125; CA15-3: carbohydrate antigen 15-3; CEA: carcinoembryonic antigen; CH: chitosan;
CSSH: L-cysteine modified chitosan; CV: cyclic voltammetry; Cyfra21–1: cytokeratin 19 fragment
antigen 21–1; DAH: 1, 7-diaminoheptane; DMF: dimethylformamide; DN: 1,5-diaminonaphthalene;
EDC: 1-Ethyl-3-(3-dimethylaminopropyl)-carbodiimide; GDPTS: (3-glycidyloxypropyl) trimethoxysilane;
GN: graphene nanosheet; GS: graphene sheet; IL-6: interleukin-6; IL-NH2: 1-aminopropyl-3-methylimidazolium
chloride; LPA: lipoic acid N-hydroxysuccinimide ester; MCM-41: multifunctional mesoporous silica;
MPA: mercaptopropionic acid; MUDA: mercaptoundecanoic acid; Nb: nanobody (antigen-binding fragments
with single domain); N-GS: nitrogen doped graphene sheet; NHS: N-Hydroxysuccinimide; NPG: nanoporous
gold; NSE: neuron specific enolase; oPD: poly(o-phenylenediamine); PA: protein A; PAMAM: polyamidoamine
dendrimers; PDA: polydopamine; PDDA: poly(diallyldimethylammonium chloride); PF-4: platelet factor-4;
PGO: porous graphene oxide; PS: polystyrene; PSA: prostate specific antigen; PSMA: prostate specific membrane
antigen; PSS: poly(sodium-p-styrenesulfonate); SAM: self-assembled monolayer; SCCA: squamous cell carcinoma
antigen; SH-GS: mercapto-functionalized graphene sheets; SPC: screen printed carbon; SPCE: screen printed carbon
electrode; TB: toluidine blue; TEPA: tetraethylene pentamine; Thi: thionine.
3. Electrochemical ELISA Based Detection
For signal detection in electrochemical ELISA-based sensors, researchers have explored the
use of various electrochemical amperometric and voltammetric techniques including differential
pulse voltammetry (DPV), linear sweep voltammetry (LSV), stripping voltammetry and square-wave
voltammetry (SWV). In general, once the analyte is captured, the sensor is incubated with the detection
molecule tagged with an electroactive agent, such as a redox molecule, nanoparticle, and quantum
dot, etc., or with an enzyme capable of generating electroactive species for signal measurement [17].
Use of redox enzyme-based indicator systems is most common and wildly applied in electrochemical
ELISA-based immunosensors [105]. Traditionally a 1:1 ratio of redox enzyme and detection molecule
is used for amplification and signal measurement. With the advances in material science and chemistry
newer nano and hybrid materials have been explored in recent years to enhance the amplification of
the signal. These advanced materials act as carriers for loading of multiple enzyme molecules and thus
enhance the signal [10,24,25]. However, the use of redox tags and enzyme-mimicking molecules are also
receiving much attention in the development of advanced immunosensors. The use of nano labels have
also provided the opportunity to achieve better signals and to develop better immunosensors [106].
The signal is usually measured via an amperometric or voltammetric technique using a potentiostat
or other low cost electrochemical systems, mainly in a three-electrode configuration. The following
sections have been divided in a way to provide more details of different strategies employed for
enhanced signal detection. Table 2 shows the details of various strategies used for the development of
detection probes for enhanced detection. Furthermore, Table 3 shows the various characteristics of the
developed immunoassays using electrochemical ELISA.
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Table 2. Strategies used for the development of detection probes for enhanced detection.
Detection Probe Components Preparation Conditions Ref.
HRP,
Anti-CEA/AuNPs-PAN@CNTs
PAN@CNTs (NH4)2S2O8 based polymerization of CNTs andaniline monomers solution in HCl at ice bath
[47]
AuNPs Citrate reduction
AuNPs-PAN@CNTs Electrostatic assembly of AuNPs
HRP-PSA
aptamer/AuNP-PAMAM
AuNP Citrate reduction
[70]thiol-PAMAM
Treating amine-terminated PAMAM dendrimer
(G4) with methyl mercaptoacetate at 50 ◦C for
18 h
AuNP-PAMAM Incubation for 5 h at RT
Thi-Anti-AFP/HRP
NPs-hollow AuNPs
hollow AuNPs
HAuCl4 reduction in N2 environment using
NaBH4, sodium citrate and CoCl2·6H2O
mixed solution
[40]
HRP NPs-hollow AuNPs
Self-assembly of L-cysteine modified HRP-NPs
prepared via desolvation followed by
glutaraldehyde chemistry;
Thi-Anti-AFP EDC/NHS chemistry
HRP, anti-AFP/Fe3O4
NPs-MSNs Fe3O4 NPs-MSNs
Treating APTES modified MSNs with
bromine-functionalized Fe3O4 NPs in EtOH
[64]
AgNPs-GOx-anti CEA AgNPs
Ag nanospheres prepared via ethylene glycol
(EG) and poly(vinyl pyrrolidone) (PVP)
based reduction
[56]
HRP-anti CA
19-9/Au@SBA-15 Au@SBA-15
incubating PDDA coated SBA-15 particles with
AuNPs solution [74]
Anti-CEA/Ag/Au–DN–GR Ag/Au–DN–GR
(i) HAuCl4, AgNO3, trisodium citrate
dihydrate and SDS mixture reduction using
NaBH4, (ii) Mix and incubate Ag/Au with
DN-graphene
[34]
PAMAM-Gr/anti-AFP-HRP PAMAM-Gr EDC/NHS chemistry [50]
HRP, GOD,
anti-AFP/SWCNHs Carboxylated SWCNHs Acid treatment of SWCNHs [73]
AuNPs-MCF
carboxy-MCF Refluxing MCF in acid
[71]
AuNPs-MCF NaBH4 based reduction of HAuCl4-MCFmixture
CHIT-PB-AuNP
CHIT-FC-AuNP
CHIT-PB Treating K3Fe(CN)6 and FeCl3 solution (pH 1.5)in CHIT
[52]CHIT-FC EDC/NHS chemistry;
AuNP binding Physical adsorption by mixing
anti-AFP2,2-AuNPs-Thi@rGO AuNPs-Thi@rGO
(i) Incubating rGO and Thi for 12 h, (ii)
Incubating Thi@rGO with AuNPs for 24 h, (iii)
Mixing FeCl3 and K3Fe(CN)6 solution (pH 1.5)
to rGO dispersion [36]
anti-CEA2,1-AuNPs-PB@rGO AuNPs-PB@rGO
(i) Mixing PB@rGO with PDDA, 30 min, (ii)
Incubation with AuNPs
Anti-CEA /PB–CS-Au and
Anti-CEA/Cd–CS-Au
PB–CS-Au and
Cd–CS-Au
(i) PBNPs and CdNPs were prepared using
FeCl3 and CdCl2 were first mixed with CS
solution in 1% acetic acid, (ii) Incubating
PBNPs and CdNPs with AuNPs
[44]
PLL-Au-Cd-Apo-Ab2 and
PLL-Au-Pb-Apo-Ab2
PLL-Au Incubating PLL with citrate reduced AuNPs
[59]
Cd-Apo and Pb-Apo
Dropwise adding metal ions (Cd2+, Pb2+) to
Apo solution pH 2 and adjusting pH to 8.5
before stirring for 3 h
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anti-CEA/PtPNPs-Cd2+ and
anti-AFP /PtPNPs-Cu2+
PtPNPs-Cd2+ and
PtPNPs-Cu2+
(i) PtPNPs synthesised from chloroplatinic acid
treatment with ascorbic acid in KOH, (ii)
Mercapto-ethylamine modification of PtPNPs
for capture of Cd2+ or Cu2+ ions
[29]
CdNCs–Au–anti-CEA and
CuNCs– Au–anti-AFP
CdNCs–Au and
CuNCs–Au
(i) Treating CdCl2 or CoCl2 in presence of CS
with K3Co(CN)6 dispersed PDDA, (ii)
Nanocubes incubation with AuNPs prepared
via citrate and NaBH4 reduction
[53]
TB/Au@KIT-6/
CMC/ILs-anti-CEA
Au@KIT-6 Treating APTES silanized KIT-6 with AuNPsprepared via NaBH4 reduction;
[45]
TB/Au@KIT-6/
CMC/ILs-Ab2
(i) Physical binding of anti-CEA on Au@KIT-6,
(ii) TB binding using EDC NHS, (iii) Mixing
and incubating with 1-butyl-pyridine
tetrafluoroborate (ILs) dissolved in CMC
Ab2/M-Alg;
(M: Cd, Pb and Cu) M-Alg
(i) Emulsion A: agitate the mixture of triton
x-100, 1-hexyl alcohol, n-octane and sodium for
more than 30 min RT, (ii) Emulsion B: agitate
mixture of triton x-100, 1-hexyl alcohol,
n-octane and Metal salt for more than 30 min
RT, (iii) Add emulsion A dropwise to emulsion
B and stir for 4 h RT, (iv) Break M-Alg using
acetone and ethanol to get M-Alg nanobeads
[43]
M/Ab2-Envision copolymer;
(M: AuNPs, CdS and PbS)
Ab2-Envision copolymer Mix and incubate Ab2 with Envision (highlybranched polymer) at 4 ◦C, 24 h
[107]
M/Ab2-Envision
copolymer
AuNP tagging via physical adsorption, CdS
and PbS were bound to HRP modified
envision-Ab2 via EDC/NHS chemistry
Au@MCM-41/TB/Ab2 Au@MCM-41
APTES modified MCM-41 was mixed with
AuNPs prepared via NaBH4 based reduction
of HAuCl4
[57]
Au@CMK-3-anti-CEA-neutral
red and
Au@CMK-3-anti-SCCA-thionine
Au@CMK-3
AuNPs were prepared from sodium citrate
based reduction of HAuCl4 were mixed and
stir with mesoporous carbon CMK-3 for 4 h
[66]
AuNPs-Ab2-Cu2+ or Pb2+
AuNPs Via sodium citrate based reduction of HAuCl4
[54]
Cu2+ and Pb2+ tagging
Cu(NO3)2 or Pb(NO3)2 incubation with
AuNPs-Ab2
Redox tag bio-dsDNA/SA/
bio-Ab2/Au/SiO2-Fe3O4
Au/SiO2–Fe3O4
(i) Nano-sized Fe3O4 via treating FeCl2-FeCl3
mixture with NaOH, (ii) Fe3O4–SiO2 via
alkaline hydrolysis of TEOS, (iii)
Au/SiO2–Fe3O4 via mixing and incubating
PDDA treated SiO2–Fe3O4 with for 20 min
[46]
bio-dsDNA/SA/
bio-Ab2/Au/SiO2-Fe3O4
(i) Incubation of biotin-Ab2 Au/SiO2-Fe3O4
12 h, 4 ◦C, (ii) Treatment with streptavidin (SA),
initiator bio-S1, bio-S2 and bio-S3 in sequence
to form
bio-dsDNA/SA/bio-Ab2/Au/SiO2-Fe3O4 via
HCR reaction
Anti-CA15-3–f-TiO2–Cd2+
nanoporous TiO2
(i) Mixing and stirring tetrabutoxytitanium
(TBOT) and ethylene glycol for 8 h, RT, (ii)
Pouring mixture in acetone-water followed by
vigorous stirring 1 h, (iii) Ethanol wash and
drying at 50 ◦C, (iv) Mix with water and reflux
for 1 h [32]
f-TiO2–Cd2+
(i) APTMS treatment to get NH2 functionalized
nanoporous TiO2 (f-TiO2), (ii) Mixing f-TiO2
with Cd(NO3)2 and stirring for 24 h at 50 ◦C
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Anti-PSA/Fc-AuNPs Fc-AuNPs Self-assembly of 6-ferrocenyl hexanethiolonto AuNPs [68]
Apt/Thi-AuNPs/
SiO2@MWCNTs
Apt/Thi-AuNPs/
SiO2@MWCNTs
(i) Treat COOH-MWCNTs (c-MWCNTs) with
PDDA, (ii) TEOS modification to get
SiO2@MWCNTs, (iii) Treatment with PDDA,
(iv) Incubation in AuNPs solution to obtain
AuNPs/SiO2@MWCNTs, (v) Mixing and
incubating with thionine 1 h, RT, (vi)
Incubation with SH-Apt solution
[58]
Ab2-PGN
rGO Mix and refluxing GO with PEI
[48]
PGN Mix H2PtCl6 with rGO and treat with NaBH4
Anti-CEA/APTES/
3DGS@MB and
anti-AFP/APTES/
3DGS@Fc-COOH
3DGS NaI based reduction of GO preparedfrom graphite
[76]
APTES/3DGS@MB,
APTES/3DGS@Fc-COOH
(i) Redox tag (MB for CEA and Fc-COOH for
AFP) modification by mixing and stirring; (ii)
Treatment with APTES to get amino
functionalized composites
CGN-Thi-anti-CEA,
CGN-DAP-anti-PSA and
CGN-Cd2+-anti-AFP
CGN
(i) Glucose carbonization in presence of sodium
citrate, (ii) AuNPs deposition on carbon
particles from HAuCl4 using microwave
reaction [75]
Thi or DAP or
Cd2+/CGN
Mixing Thi or DAP or Cd(NO3)2 with CGN
and stirring for 5 h
M-Pt-Ab2 M-Pt Ascorbic acid based reduction of K2PtCl4 [30]
Anti-CA72-4/PANi–Au
AMNPs PANi–Au AMNPs
Mix and incubate aniline in hexane with
HAuCl4 aqueous solution at 45 ◦C overnight
[55]
Fe3O4@SiO2/Fc/GA/anti-CEA Fe3O4@SiO2/Fc/GA/
(i) Fe3O4 via solvothermal method; (ii)
Treatment with TEOS to obtain Fe3O4@SiO2;
(iii) Treatment with APTES to get
Fe3O4@SiO2–NH2; (iv) Treatment with
EDC/NHS activated Fc-COOH followed by
treatment with GA
[35]
Anti-SCCA/Pd–Au/C Pd–Au/C
Mixing activated carbon, PdCl2, HAuCl4 and
H2O-tetrahydrofuran via ultra-sonicating and
stirring followed by treatment with NaBH4
and Na2CO3
[28]
Cu@Ag-CD/anti-CEA Cu@Ag-CD
CD-ascorbic acid (pH 11) solution based
sequential reduction of CuSO4·5H2O and
AgNO3 solution in ammonia, followed by
mixing and stirring with HS-β-CD overnight;
Obtained Cu@Ag-CD was used for EDC/NHS
based binding of Ab2 modified ADA-COOH
[37]
Fe3O4@C@Pd/anti-AFP Fe3O4@C@Pd
(i) Fe3O4@C magnetic nanoparticles via
hydrothermal process; (ii) Treatment with
PDDA followed by mixing and incubation with
PDNPs prepared via citrate and NaBH4 based
reduction of Na2PdCl4
[33]
Anti-CA15-3/NP-PtFe NP-PtFe By removing Al using NaOH from ternaryPtFeAl alloy with 80%Al [31]
Anti-AFP/PdNi/N-GNRs PdNi/N-GNRs
(i) N-GNRs powders via microwave-assisted
treatment of N-MWCNTs, (ii) Mix N-GNRs
with aqueous solution of Na2PdCl4,
NiCl2·6H2O, and glutamate in ethylene glycol
(EG), (pH 11) and stirring it for 2h followed by
heating at 160 ◦C for 6 h in autoclave to get
PdNi/N-GNRs
[39]
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Pb2+@Au@MWCNTs-Fe3O4/
anti-AFP
Pb2+@Au@
MWCNTs-Fe3O4
(i) MWCNTs-Fe3O4 via autoclaving the
mixture of acid treated MWCNTs, FeCl3.6H2O
and sodium acetate, (ii)
Amino-functionalization via APTES
modification, (iii) Mixing and incubation with
AuNPs prepared via citrate reduction; (iv)
Treatment with lead nitrate solution 24 h to get
Pb2+@Au@MWCNTs-Fe3O4
[49]
Au/Ag/Au@anti-SCCA Au/Ag/Au
(i) Mix AuNPs, ascorbic acid, and AgNO3 in
CTAB solution, (ii) Add NaOH dropwise with
vigorous stirring to get yellow-golden colored,
silver coated Au particles, (iii) Mix with
HAuCl4 and ascorbic acid and stirred
vigorously to obtain dark-blue Au/Ag/Au
NPs solution
[41]
Anti-AFP/Pd/
APTES-M-CeO2-GS
Pd/APTES-M-CeO2-GS
(i) The Pd octahedral NPs via sonicating
followed by heating the mixture of
1-ethenyl-2-pyrrolidinone homopolymer (PVP),
citric acid, and Na2PdCl4 dissolved in ethanol
and water at 80 ◦C with stirring and refluxing
for 3 h, (ii) M-CeO2-GS prepared by dissolving
Ce(NO3)3·6H2O into water followed by adding
C2H5COOH, ethylene glycol and GO and then
treating at 180 ◦C for 200 min followed by
cooling, centrifuging the ppt and drying at
50 ◦C for 12 h, (iii) APTES modification of
M-CeO2-GS by refluxing, (iv) Pd binding by
sonication and stirring to get
Pd/APTES-M-CeO2-GS
[51]
Anti-SCC-Pt–Fe3O4 Pt–Fe3O4
(i) Mix platinum acetylacetonate, oleic acid,
oleylamine and octadecane under argon
atmosphere followed by heating to 120 ◦C, (ii)
add Fe(CO)5 heat at 280 ◦C, 20 min, (iii)
Precipitation using ethanol addition
[65]
Anti-AFP/Pt@CuO-MWCNTs Pt@CuO-MWCNTs
(i) Acid treated MWCNTs mixed with
Cu(CH3COO)2·H2O were grounded and
calcinated at 350 ◦C in argon, followed by
addition of NH4OH solution, (ii) MWCNTs
addition followed by ageing and calcination to
get CuO/MWCNTs composite, (iii) Pt loading
by adding CuO/MWCNTs nanocomposites to
K2PtCl4 solution followed by Pt salt reduction
[38]
M-Pd@Pt/NH2-GS/anti-PSA
NH2-GS
(i) Mix GO and ethylene glycol under
ultrasonication followed by ammonia water
addition, (ii) Autoclave for solvothermal
reaction at 180 ◦C, 10 h
[78]
M-Pd@Pt
(i) Mix Pluronic F127 with aqueous solution of
K2PtCl4, Na2PdCl4 and hydrochloric, (ii)
Reduction using ascorbic acid at 35 ◦C for 4 h
M-Pd@Pt/NH2-GS Mix and sonicate NH2-GS and M-Pd@Pt for 1 h
Ir NPs-anti-CEA PVP stabilized Ir NPs
(i) Add aqueous IrCl3 solution dropwise to
ethanol solution containing PVP followed by
mixing and stirring at 25 ◦C for 12 h, (ii)
Refluxed in air at 100 ◦C for 6 h followed
by evaporation
[79]
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PBG-Au-anti-CEA;
PPP-Au-anti-NSE;
PTBO-Auanti-CA125;
PMCP-Au-anti-Cyfra21–1;
Cd NCs-Auanti-SCCA
PBG-Au
Add and stir TTAB to brilliant green aqueous
solution followed by HAuCl4 addition and
agitation for 4 h, RT
[80]
PPP-Au
Add water with stirring to DMF solution of
N-phenyl-p-phenylenediamine followed by
HAuCl4 addition and agitation for 4 h, RT
PTBO-Au Add HAuCl4 to toluidine blue o aqueoussolution and agitate for about 4 h, RT
PMCP-Au
Add and stir DTAB to m-cresol purple ethanol
solution followed by HAuCl4 addition and
agitation for 4 h, RT
Cd NCs-Au Mix Cd NCs with gold colloid and stirred for4 h
HRP-anti-CYFRA21-1/
AuNPs/Thi/MWCNT-NH2
AuNPs HAuCl4 reduction using NaBH4 inThi/MWCNT-NH2 solution
[84]
MWCNT-NH2
Acid treatment of MWCNT to get
MWCNT-COOH followed by treatment with
HMDA in presence of DCC for 96 h at 120 ◦C
anti-AFP-Co3O4@MnO2-Thi
Co3O4@MnO2
Mixture of Co(CH3COO)2·4H2O and MnO2
nanotubes in ammonium hydroxide autoclaved
at 150 ◦C, 5 h followed by calcination at 300 ◦C,
1 h
[85]
Co3O4@MnO2-Thi
Co3O4@MnO2 treatment with APTES at 70 ◦C,
1.5 h followed by incubation with Thi at 95 ◦C,
1 h
anti-AFP-
Co3O4@MnO2-Thi
EDC/NHS chemistry
antiHER2/
Hyd@AuNPs-APTMS-Fe3O4
antiHER2/
Hyd@AuNPs-APTMS-
Fe3O4
AuNPs preparation using HAuCl4 reduction
via NaBH4, sodium citrate followed by
treatment with APTMS-Fe3O4. Resulting
AuNPs-APTMS-Fe3O4 were treated with
thiolated anti-HER2 followed by treatment
with hydrazine
[86]
Anti-CEA-AuNPs-Fc
AuNPs Reduction of chloroauric acid withtrisodium citrate
[87]
Anti-CEA-AuNPs-Fc Physical immobilization of anti-CEA onAuNPs followed by chemisorption of Fc-SH
HRP-anti-CEA-
AuNPs-TiO2-graphene
TiO2-graphene
Sonicate graphene with dopamine for 1 h,
followed by stirring with TiO2
[89]
HRP-anti-CEA-
AuNPs-TiO2-graphene
Treat TiO2-graphene with HAuCl4 under
ultraviolet irradiation followed by physical
adsorption of HRP-anti-CEA
PtCu@rGO/
g-C3N4/anti-PSA
PtCu@rGO/
g-C3N4/anti-PSA
Physical adsorption of anti-PSA on
PtCu@rGO/g-C3N4
[90]
M-Pd@Pt/NH2-GS/anti-PSA
NH2-GS
GO prepared via modified Hummer’s method
was mixed with ethylene glycol and ammonia
followed by autoclaving at 180 ◦C for 10 h
[78]
M-Pd@Pt
Pluronic F127 was mixed with K2PtCl4 and
Na2PdCl4 in HCl followed by reducing with
ascorbic acid
Anti-AFP-Pt
NPs/Co3O4/graphene
Pt
NPs/Co3O4/graphene
Mix GO and Co(NO3)2·6H2O in ethanol and
add ammonia solution followed by autoclaving
at 190 ◦C for 24 h. Obtained Co3O4/graphene
was mixed with Na2PtCl4 in ethanol aqueous
solution and treat with NaBH4
[91]
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GS-Fe3O4/Au@Ag/
Ni2+-anti-CEA
NH2-GS-Fe3O4
GO prepared via modified Hummer’s method
was mixed with clear solution of FeCl3·6H2O
in ethylene glycol along with NaAc and
ethanediamine and autoclaved at 200 ◦C for 8 h.
Resulting GS-Fe3O4 was treated with APTES to
get NH2-GS-Fe3O4
[92]
Au@Ag
AuNPs prepared via citrate reduction were
mixed with ascorbic acid, AgNO3 and CTAB
solution and treated with NaOH
GS-Fe3O4/Au@Ag/
Ni2+-anti-CEA
GS-Fe3O4/Au@Ag made by mixing
NH2-GS-Fe3O4 and Au@Ag were dispersed in
Ni(NO3)2·6H2O solution and stir for 24 h, anti
CEA was immobilized via physical adsorption
Ag NPs-MWCNTs/
MnO2-Anti-CEA
Ag NPs-MWCNTs/
MnO2
Acid treated MWCNTs were dispersed in
KMnO4 solution and treated with MnSO4.
Obtained MWCNTs/MnO2 were mixed with
AgNO3 in water followed by reduction NaBH4
[93]
PdCu-anti-CEA PdCu Using AA as reducing agent and HDPC asgrowth inhibitor [95]
anti-AFP-GNPs-HRP GNP Citrate reduction [96]
anti-AFP/HRP-Au@ZnO Au@ZnO C18N3 was added to mixture of Zn(NO3)2 andHAuCl4 and heated at 145 ◦C, 5 h
[97]
anti-PSA/AuNPs AuNPs Citrate reduction in cold for smaller size and inboiling condition for large size [98]
Co3O4@CeO2-Au@Pt-
anti-SCCA
Co3O4@CeO2
Co(NO3)2·6H2O solution was treated with
NaOH at 180 ◦C, 5 h. Obtained Co3O4 cubes
were mixed in ethanol aqueous solution
followed by addition of Ce(NO3)3 and HMT
and refluxing at 70 ◦C, 2 h
[99]
Au@Pt
Citrate reduced AuNPs were mixed with
H2PtCl6 under boiling conditions followed by
reduction with AA
Co3O4@CeO2-Au@Pt
APTES treated Co3O4@CeO2 were mixed with
Au@Pt and stir for 12 h at room temperature.
Anti-AFP/Au@Ag/
PDA-PR-MCS
PR-MCS
C6H5OH and HCHO were added to solution
containing NH4OH and C2H5OH and
autoclaved at 100 ◦C, 24 h. Product was mixed
with KOH and treated at 350 ◦C, 1 h followed
by at 700 ◦C, 2 h [100]
Au@Ag
Citrate reduced AuNPs were mixed with
AgNO3 solution and treated with NaBH4
solution
Au@Ag/PDA-PR-MCS
PR-MCS dispersed in tris buffer was treated
with Dopamine hydrochloride 24 h and mixed
with Au@Ag solution
MSN-MB/PDA-anti-PSA
MSN Mixture of CTAB and pluronics F127 in ethanol,water and ammonia was treated with TEOS
[101]
MSN-MB/PDA MB loaded MSN was treated with dopamine intris buffer, pH 8.5
Au@Pt
DNs/NG/Cu2+-anti-CEA
NG
GO prepared via modified Hummer’s method
was treated with ammonia solution at 90 ◦C,
4 h
[103]
Au@Pt DNs
NaBH4 and AA reduced HAuCl4 and CTAB
solution was mixed with K2PtCl4 and AA and
treated at 60 ◦C, 12 h
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Au@Ag-Cu2O/anti-PSA Au@Ag-Cu2O
Citrate reduced AuNPs were mixed with
CTAC and AgNO3 followed by reduction
using AA at 30 ◦C, 2 h.
Obtained Au@Ag solution was mixed with
CuCl2 and SDS followed by treatment with
NaOH and NH2OH·HCl
[104]
Notes: AA: ascorbic acid; Apo: apoferritin; Cd NCs-Au: Cd nanocubes-gold; CdNCs and CuNCs: Cd3[Co(CN)6]2
and Cu3[Co(CN)6]2 nanocubes; CTAB: hexadecyl trimethyl ammonium bromide; CTAC: cetyltrimethylammonium
chloride; HDPC: hexadecylpyridinium chloride monohydrate; HMDA: hexamethylenediamine; HMT:
hexamethylenetetramine; Ir NPs: iridium nanoparticles; M-Alg: metal alginate nanobeads; MCF: mesoporous
carbon form; MCM-41: multifunctional mesoporous silica; M-Pd@Pt/NH2-GS: mesoporous core-shell Pd@Pt
nanoparticles loaded by amino group functionalized graphene; M-Pt NPs: mesoporous platinum nanoparticles;
MSNs: mesoporous silica nanoparticles; N-MWCNTs: N-doped multi-walled carbon nanotubes; PBG-Au: poly
(brilliant green)-gold; PDDA: poly(diallyldimethylammonium chloride); PMCP-Au: poly (m-cresol purple)-gold;
PPP-Au: poly (N-phenyl-p-phenylenediamine)-gold; PTBO-Au: poly (toluidine blue o)-gold; PtPNPs: platinum
porous nanoparticles; PVP: polyvinylpyrrolidone; SDS: sodium dodecyl sulfate.
Table 3. Characteristics of the developed immunoassays using electrochemical ELISA.
Probe Immunosensor Conditions Characteristics Ref.
[DP]: anti-HER2-HRP
[Anal]: HER2
[DM]: HQ
[Tran]: amperometry at −280 mV
[IC]: (i) anal for 2 min at RT, (ii)
[DP] for 20 min
[MC]: 2.5 mm H2O2 with HQ in
citrate buffer
[L]: 1 and 200 µg/mL, [LgS]
[DL]: 1 µg/mL
[S]: 18.23 µA/(µg/mL)
[SL]: 3 weeks
[CR]: 0.9591
[63]
[DP]: anti-CEA-HRP/
AuNPs-PAN@CNTs
[Anal]: CEA
[DM]: H2O2
[Tran]: DPV in 0.2 to −0.8 V, [PA]
50 mV
[IC]: (i) CEA, (ii) [DP] for 55 min
at 37 ◦C, sequentially
[MC]: 4 mM H2O2 in 5.0 mL PBS
[L]: (i) 0.02–3.0 ng/mL, (ii)
3.0–80 ng/mL [LS]
[DL]: 0.008 ng/mL
[S]: (i) 13.9465 µA/(ng/mL),
(ii) 0.7342 µA/(ng/mL)
[SL]: 30 days
[CR]: (i) 0.9875, (ii) 0.9960
[47]
[DP]: AuNP–PAMAM
dendrimer/PSA–aptamer-HRP
[Anal]: PSA
[DM]: thionine
[Tran]: DPV in −0.4 to −0.1 V
[IC]: (i) PSA conc. for 15 min, (ii)
[DP] for 20 min
[MC]: 3 mM H2O2
[L]: 0.1 pg/mL to 90 ng/mL
[LS]
[DL]: 10 fg/mL
[S]: 0.3635 µA/(pg/mL)
[SL]: 3 weeks
[CR]: 0.9831
[70]
[DP]: HRP-HRP-NP-hollow
Au-NP-Thi@anti-AFP
[Anal]: AFP
[DM]: thionine
[Tran]: DPV in −0.4 to 0 V
[IC]: (i) AFP conc for 16 min,
37 ◦C, (ii) [DP] for 30 min, RT
[MC]: 4.2 mM H2O2
[L]: 0.025 to 5.0 ng/mL [LgS]
[DL]: 8.3 pg/mL
[S]: 7.649 µA/(ng/mL)
[SL]: 30 days
[CR]: 0.9949
[40]
[DP]: anti-AFP,
HRP/MSNs-Fe3O4
[Anal]: AFP
[DM]: thionine
[Tran]: CV in −0.6 to 0.6 V (vs.
SCE) at 100 mV/s in PBS (pH 7.4)
[IC]: (i) AFP, (ii) [DP] for 1 h,
sequentially
[MC]: 5 mmol/L H2O2 in PBS
[L]: 0.01 to 25 ng/mL [LS]
[DL]: 4 pg/mL
[SL]: 15 days
[64]
[DP]: GOx/anti-CEA/AgNPs
[Anal]: CEA
[DM]: H2O2
[Tran]: DPV in −0.2 to −0.8 V,
[PA]: 50 mV, [PW]: 20 ms
[IC]: (i) CEA conc 40 min, RT, (ii)
[DP] 1 h, 4 ◦C
[MC]: PBS + 1% glucose
[L]: 1 pg/mL to 50 ng/mL
[LgS]
[DL]: 0.27 pg/mL
[S]: 8.281 µA/(ng/mL)
[SL]: 30 days
[CR]: 0.9971
[56]
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[DP]: HRP-Ag@BSA-anti-CEA
[Anal]: CEA
[DM]: tyramine
[Tran]: DPV in 0 to -600 mV vs.
SCE [PA]: 50mV, [PW]: 50 ms in
PBS
[IC]: (i) CEA conc 40 min, RT, (ii)
[DP] 40 min, RT, (iii) 2 mM H2O2 +
HRP-tyramine conjugates 10 min
at RT
[MC]: 2.5 mM H2O2 in PBS
[L]: 0.005–80 ng/mL [LgS]
[DL]: 5.0 pg/mL
[S]: 1.617 µA/(ng/mL)
[SL]: 28 days
[CR]: 0.9867
[108]
[DP]: HRP/HRP-anti-CA
19-9/Au@SBA-15
[Anal]: CA 19-9
[DM]: H2O2
[Tran]: chronoamperometry PBS
pH 6 at −0.2 V
[IC]: (i) CA 19-9 conc 1 h, 37 ◦C;
(ii) [DP] 1 h, 37 ◦C
[MC]: 3 mM H2O2 in PBS
[L]: 0.05 to 15.65 U/mL [LgS]
[DL]: 0.01 U/mL
[S]: 20.51 g/L
[SL]: 30 days
[CR]: 0.992
[74]
[DP]: anti-CEA
–Ag/Au–DN-graphene
[Anal]: CEA
[DM]: Ag
[Tran]: CV in −0.6 to1.0 V (vs.
SCE) at 50 mV/s
[IC]: (i) CEA conc 30 min, (ii) [DP]:
40 min
[MC]: 0.1M PBS (pH7.0).
[L]: 10 to 1.2 × 105 pg/mL
[LgS]
[DL]: 8 pg/mL
[S]: 0.494 µA/(ng/mL)
[CR]: 0.9899
[34]
[DP]:
PAMAM-Gr/anti-AFP-HRP
[Anal]: AFP
[DM]: hydroquinone
[Tran]: (i) amperometric at −0.2 V,
(ii) CV −0.5 to +0.5 V, 50 mV/s
[IC]: (i) AFP conc 40 min, 37 ◦C,
(ii) [DP]: 40 min, 37 ◦C
[MC]: PBS containing 1 mM
hydroquinone + 2 mM H2O2
[L]: 1.0–100 ng/mL [LS]
[DL]: 0.45 ng/mL [50]
[DP]:
Au@Pd-Gra/Thi-anti-CA
19-9/HRP
[Anal]: CA19-9
[DM]: Thionine
[Tran]: DPV in −0.4–0 V, [PA]:
50 mV, [PW]: 50 ms, [PP]: 0.2 s
[IC]: (i) CA 19-9 conc 40 min,
25 ◦C, (ii) [DP]
[MC]: 1.5 mM H2O2
[L]: 0.015 to 150 U/mL [LgS]
[DL]: 0.006 U/mL
[S]: 9.8328 µA/(U/mL)
[SL]: 30 days
[CR]: 0.9982
[72]
[DP]: HRP, GOD,
anti-AFP/SWCNHs
[Anal]: AFP
[DM]: 4-CN
[Tran]: Impedance
[IC]: (i) AFP conc 40 min, 37 ◦C,
(ii) [DP] 40 min, 37 ◦C, (iii) 1.0 mM
4-CN and 10.0 mM glucose in
10mM PBS 15 min, RT
[MC]: 0.01M PBS (pH 7.4)
containing 5 mM FeCN63−/4−
and 0.1 M KCl
[L]: 0.001 to 60 ng/mL [LgS]
[DL]: 0.33 pg/mL
[S]: 230.60 Ω/(ng/mL)
[SL]: 30 days
[CR]: 0.996
[73]
[DP]: anti-CEA/Au/MCF
[Anal]: CEA
[DM]: Ag
[Tran]: ASV in −0.08 to 0.2 V,
50 mV/s
[IC]: (i) CEA conc 40 min, 37 ◦C,
(ii) [DP] 40 min, 37 ◦C, (iii)
silver-deposition with enhancer
solutions 4 min, 37 ◦C,
[MC]: 1.0 M KCl
[L]: 0.05 pg/mL to 1 ng/mL
[LgS]
[DL]: 0.024 pg/mL
[SL]: 15 days
[CR]: 0.9997
[71]
[DP]:
anti-AFP/CHIT–PB–AuNP;
anti-CEA/CHIT–Fc–AuNPs,
[Anal]: CEA, AFP
[DM]: PB, Fc
[Tran]: DPV in −0.2 to 0.8 V
[IC]: 45 min incubation for CEA,
AFP concentration
[MC]: PBS
[L]: 0.05–100 ng mL−1 for AFP
and CEA [LgS]
[DL]: 0.03 ng mL−1 and
0.02 ng mL−1 for AFP and
CEA
[S]: 0.47067 µA/(ng/mL),
0.51106 µA/(ng/mL) for AFP
and CEA
[CR]: 0.99712 for AFP and
0.99806 for CEA
[52]
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[DP]:
anti-AFP-AuNPs-Thi@rGO
and
anti-CEA-AuNPs-PB@rGO
[Anal]: CEA, AFP
[DM]: PB, Thionine
[Tran]: DPV 600 to −600 mV; [PA]
50 mV.
[IC]: (i) CEA/AFP conc 50 min,
37 ◦C, (ii) [DP] 50 min, 37 ◦C
[MC]: PBS pH 6.5
[L]: 0.6–80 ng/mL for both
[LS]
[DL]: 0.12 ng/mL and
0.08 ng/mL for CEA and AFP
[S]: 0.0188 µA/(ng/mL),
0.0273 µA/(ng/mL) for CEA
and AFP
[SL]: 30 days
[CR]: 0.9908, 0.9936 for CEA
and AFP
[36]
[DP]: Anti-CEA/PB–CS-Au
and anti APF/Cd–CS-Au
[Anal]: CEA, AFP
[DM]: PB, Cd
[Tran]: DPV in −0.1V to 0.9V (vs.
Ag/AgCl), [PA]: 50 mV, [PW]:
50 ms
[IC]: (i) CEA/AFP conc 40 min, (ii)
[DP] mixture 1:1
[MC]: 0.1 M pH 6.5 phosphate
buffered solution (PBS)
[L]: 0.01 to 100 ng/mL range
for both [LgS]
[DL]: 0.006 ng/mL for AFP
and 0.01 ng/mL for CEA
[S]: 1.771 µA/(ng/mL),
1.751 µA/(ng/mL) for CEA
and AFP
[CR]: 0.996 and 0.995 for CEA
and AFP
[44]
[DP]:
PLL-Au-Cd-Apo-anti-AFP
and PLL-Au-Pb-Apo-anti-CEA
[Anal]: AFP and CEA
[DM]: Cd, PB
[Tran]: SWV scan from −1.0 to
−0.3 V with frequency of 15 Hz,
[PA]: 25 mV, potential step 4 mV,
quiet time 2 s to measure AFP and
CEA at −0.78 V and −0.53 V
[IC]: (i) CEA/AFP conc 20 min,
RT, (ii) [DP] 20 min, RT
[MC]: (i) immuno-complex in
acetate buffer containing 400 µg/L
bismuth, (ii) deposition of
bismuth film and metal ions in
situ at −1.2 V for 120 s
[L]: 0.01–50 ng/mL for both
[LgS]
[DL]: 4 pg/mL for both
[S]: 6.65 µA/(ng/mL),
6.62 µA/(ng/mL), for AFP
and CEA
[SL]: 25 days
[CR]:0.992, 0.994 for AFP and
CEA
[59]
[DP]: anti-CEA-PtPNP-Cd2+
and anti-AFP-PtPNPs-Cu2+
[Anal]: CEA and AFP
[DM]:Cd2+, Cu2+
[Tran]: DPV in 0.2 to −0.9 V with
[PA]: 50 mV, [PW]: 50 ms and
quiet time of 2 s were recorded for
CEA and AFP at −0.736 V and
0.004 V respectively
[IC]: (i) CEA/AFP conc 1 h, 37 ◦C,
(ii) [DP] 1 h, 37 ◦C
[MC]: acetate buffer solution
(0.2 M, pH 4.5).
[L]: 0.05 ng/mL to 200 ng/mL
range for both CEA and AFP
[LgS]
[DL]: 0.002 ng/mL and
0.05 ng/mL for CEA and AFP
[S]: 2.26 µA/(ng/mL),
1.06 µA/(ng/mL), for CEA
and AFP
[CR]: 0.997, 0.998 for CEA and
AFP
[29]
[DP]: CdNCs–Au–anti-CEA
and CuNCs–Au– anti-AFP
[Anal]: CEA and AFP
[DM]: CdNCs and CuNCs
[Tran]: SWV in 0.1 to −0.9 V with
[PA]: 25 mV, pulse frequency
15 Hz, were recorded for CEA and
AFP at −0.7 V and −0.1 V (vs.
Ag/AgCl),
[IC]: (i) CEA/AFP conc 50 min,
37 ◦C, (ii) [DP] 50 min, 37 ◦C
[MC]: acetate buffer solution
(0.2 M, pH 6).
[L]: 0.025 to 250 ng/mL range
for both [LgS]
[DL]: 0.0175 ng/mL and
0.0109 ng/mL for CEA and
AFP
[S]: 4.31 µA/(ng/mL),
3.858 µA/(ng/mL), for CEA
and AFP
[CR]: 0.998 for CEA and AFP
[53]
[DP]: TB/Au@KIT-6/CMC/
ILs-anti-CEA
[Anal]: CEA
[DM]: TB
[Tran]: DPV in −0.6 V to 0 V
[IC]: (i) CEA conc 1 h, RT, (ii) [DP]
1 h
[MC]: PBS pH 6.8
[L]: 10−5 ng/mL to
102 ng/mL [LgS]
[DL]: 3.3 fg/mL
[S]: 3.32 µA/(ng/mL)
[SL]: 2 weeks
[CR]: 0.99
[45]
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[DP]: Cd-Alg-anti-AFP,
Pb-Alg-anti-CEA and
Cu-Alg-anti-PSA
[Anal]: AFP, CEA and PSA
[DM]: Cd, Pb, Cu
[Tran]: DPV in −0.9 to 0.2 V to
measure AFP, CEA and PSA at
−0.76 V, −0.5 V and 0.12 V (vs.
Ag/AgCl)
[IC]: (i) CEA/AFP/PSA conc
50 min, 37 ◦C, (ii) [DP] 50 min,
37 ◦C
[MC]: acetate buffer solution
(0.2 M, pH 5).
[L]: 0.01 to 100 ng mL−1 for all
[DL]: 0.01, 0.0086 and
0.0075 ng/mL for AFP, CEA
and PSA
[S]: 5.548 µA/(ng/mL),
3.737 µA/(ng/mL),
4.586 µA/(ng/mL), for AFP,
CEA and PSA
[SL]: 15 days
[CR]: 0.993, 0.994, 0.996 for
AFP, CEA and PSA
[43]
[DP]:
anti-CA19-92/Envision/Au,
anti-AFP2/Envision/CdS and
anti-CEA2/Envision/PbS
[Anal]: CA19-9, CEA and AFP
[DM]: Au (via CSV), CdS, PbS
(via ASV)
[Tran]: ASV with accumulation at
−1.2 V for 120 s, and scanning
from −1.0 to −0.3 V, with [PS]: 4
mV, frequency 15 Hz, and [PA]: 25
mV. CSV +1.3 V for 30 s,
immediately followed by DPV
detection from +0.6 V to 0 V, with
[PS]: 4 mV, [PA]: 50 mV, and pulse
period of 0.2 s.
[IC]: (i) Ca 19-9/CEA/AFP conc
30 min, RT, (ii) [DP] 30 min, RT
[MC]: (i) GCE was incubated in
pH 2.0 bismuth nitrate solution in
acetate and treated at −1.2 V for
120 s, (ii) immune-complex in
0.1 M HCl
[L]: 5 pg/mL–100 ng/mL,
1 pg/mL–50 ng/mL, and
1 pg/mL–50 ng/mL for
CA19-9, CEA and AFP [LgS]
[DL]: 0.3, 0.05, 0.02 pg/mL for
CA19-9, CEA and AFP
[S]: 6.65, 7.32,
0.60 µA/(ng/mL) for AFP ,
CEA and CA19-9
[SL]: 60 days
[CR]:0.99, 0.997, 0.993 for AFP ,
CEA and CA19-9
[107]
[DP]:
Au@MCM-41/TB/anti-AFP
[Anal]: AFP
[DM]: TB
[Tran]: DPV in −0.6 V to 0.2 V.
[IC]: (i) AFP conc 1 h, RT, (ii) [DP]
1 h, RT
[MC]: PBS pH 6.8
[L]: 10−4 ng/mL to
103 ng/mL [LgS]
[DL]: 0.05 pg/mL
[S]: 1.43 µA/(ng/mL),
[SL]: 2 weeks
[CR]: 0.99
[57]
[DP]:
Au@CMK-3-anti-CEA-neutral
red and
Au@CMK-3-anti-SCCA-thionine
[Anal]: CEA and SCCA
[DM]: neutral red, thionine
[Tran]: DPV in −0.7 to 1 V for
recording −0.62 V (neutral red),
and −0.17V (thionine)
[IC]: (i) CEA/SCCA conc 1 h, RT,
(ii) [DP] 1 h
[MC]: PBS pH 7.4
[L]: 0.05 to 20 ng/mL and 0.03
to 20 ng/mL range for CEA
and SCCA [LS]
[DL]: 0.013 ng/mL and
0.010 ng/mL for CEA and
SCCA
[SL]: 10 days
[66]
[DP]: AuNPs–anti-CEA–Cu2+
and AuNPs–anti-AFP–Pb2+
[Anal]: CEA and AFP
[DM]: Cu2+, Pb2+
[Tran]: DPV in −0.7 V to 0.3 V (vs.
SCE), [PA] 50 mV, [PW] 50 ms
[IC]: (i) CEA/AFP conc 35 min,
37 ◦C, (ii) [DP] 45 min, 37 ◦C
[MC]: HAc/NaAc (0.2 M, pH 3.5)
[L]: 0.01–50 ng/mL for both
[LgS]
[DL]: 4.6 pg/mL and
3.1 pg/mL for CEA and AFP
[S]: 3.3 µA/(ng/mL),
4.86 µA/(ng/mL), for CEA
and AFP
[CR]:0.9967, 0.9991 for CEA
and AFP
[54]
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[DP]: Aq-SA/bio-dsDNA/SA/
bio-anti-AFP/Au/SiO2–Fe3O4,
Thi-SA/bio-dsDNA/SA/
bio-anti-CEA/Au/SiO2–Fe3O4,
Co-SA/bio-dsDNA/SA/
bio-anti-CA125/Au/SiO2–Fe3O4,
Fc-SA/bio-dsDNA/SA/
bio-anti-PSA/Au/SiO2–Fe3O4
[Anal]: AFP, CEA, CA125 and PSA
[DM]: Aq, Thi, Co, Fc
[Tran]: DPV in −0.7 to 0.7 V incre:
0.004 V, [PA]: 0.05 V, [PW]: 0.05 s,
sampling width: 0.0167 s, pulse
period: 0.2 s to record AFP at
−0.52 V, CEA at −0.21V, CA125 at
0.0V, PSA at 0.26V
[IC]: (i) AFP/CEA/CA125/PSA
conc 40 min, 37 ◦C, (ii) [DP]:
40 min, 37 ◦C
[MC]: PBS 0.1 M, pH: 7.4
[L]: 0.2 to 800 pg/mL, 0.2 to
600 pg/mL, 0.2 to 1000 pg/mL,
and 0.2 to 800 pg/mL for AFP,
CEA, CA125 and PSA [LgS]
[DL]: 62, 48, 77 and 60 fg/mL
for AFP, CEA, CA125 and PSA
[S]: 22.71 µA/(pg/mL),
21.91 µA/(pg/mL),
33.69 µA/(pg/mL),21.30 µA/
(pg/mL), for for AFP, CEA,
CA125 and PSA
[SL]: 14 days
[CR]: 0.9797, 0.9696, 0.9791,
0.9786 for AFP, CEA, CA125
and PSA
[46]
[DP]: anti-CEA-AuNP-So
[Anal]: CEA
[DM]: MB
[Tran]: DPV 0 to −500 mV vs SCE
[IC]: (i) CEA conc + [DP] 40 min,
RT, (ii) hybridization mix 80 min,
RT, (iii) hemin incubation 50 min
RT, (iv) methylene blue incubation
30 min at RT
[MC]: PBS (pH 7.0) containing
3.0 mM H2O2
[L]: 1.0 fg/mL to 20 ng/mL
[LgS]
[DL]: 0.5 fg/mL
[S]: 1.9636 µA/(ng/mL),
[SL]: 30 days
[CR]: 0.9973
[60]
[DP]: anti-CA15-3–f-TiO2–Cd2+
[Anal]: CA15-3
[DM]: Cd2+
[Tran]: SWV in −1 to −0.45 V
[IC]: (i) CA15-3 conc 1 h, 4 ◦C, (ii)
[DP] 1 h, 4 ◦C
[MC]: PBS (pH 5.4)
[L]: 0.02–60 U/mL [LS]
[DL]: 0.008 U/mL
[S]: 1.806 µA/(U/mL),
[SL]: 4 weeks
[CR]: 0.998
[32]
[DP]: PtNP@ICP-anti-PSA
[Anal]: PSA
[DM]: FcDA
[Tran]: DPV at 0.31 V vs. SCE
[IC]: (i) PSA conc 30 min, RT, (ii)
[DP] 30 min, RT,
[MC]: 5.0 mM H2O2 in the PBS
pH 7.0
[L]: 0.001 to 60 ng/mL [LgS]
[DL]: 0.3 pg/mL
[S]: 1.85129 µA/(ng/mL),
[SL]: 1 week
[CR]: 0.988
[61]
[DP]: anti-PSA-Fc-AuNP
[Anal]: PSA
[DM]: Fc
[Tran]: DPV in 0 to 0.6 V
[IC]: (i) PSA conc 75 min, 37 ◦C,
(ii) [DP] 90 min, 37 ◦C,
[MC]: PBS
[L]: 10 pg/mL to 100 ng/mL
[LS]
[DL]: 5.4 pg/mL
[S]: 0.137 µA/(ng/mL),
[CR]: 0.9907
[68]
[DP]: Aptamer/Thi-AuNPs/
SiO2@MWCNTs
[Anal]: MUC 1
[DM]: Thionine
[Tran]: DPV in −0.33 to −0.1 V
[IC]: (i) MUC1 conc 40 min, 37 ◦C,
(ii) [DP] 40 min, 37 ◦C,
[MC]: PBS pH 7.4
[L]: 10−3 to 1 nM, 1–100 nM
[LS]
[DL]: 1 pM
[S]: 1.647 nA/nM
[SL]: 30 days
[CR]: 0.98
[58]
[DP]:
HRP-GOD/Fc-anti-AFP/PGN,
HRP-GOD/Thi-anti-CEA/PGN
[Anal]: CEA and AFP
[DM]: Fc, Thi
[Tran]: SWV in −0.6 V to 0.6 V
with a frequency of 15 Hz and a
[PA]: of 25 mV (vs. SCE) to record
Thi (at −0.15 V) and Fc (at 0.35 V)
[IC]: (i) CEA/AFP conc 45 min,
37 ◦C, (ii) [DP] 45 min, 37 ◦C,
[MC]: PBS (0.1 M pH 6.5) with
4 mM glucose
[L]: 0.01–100 ng/mL for both
[LgS]
[DL]: 1.64 pg/mL and
1.33 pg/mL for CEA and AFP
[SL]: 30 days
[CR]: 0.998, 0.994 for CEA
and AFP
[48]
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[DP]: 3DGS@MB-anti-CEA
and 3DGS@Fc-anti-AFP
[Anal]: CEA and AFP
[DM]: MB, Fc
[Tran]: DPV in −0.4 to 0.4 V with
[PA]: 50 mV and [PW] 50 ms
[IC]: (i) CEA/AFP conc 40 min,
RT, (ii) [DP],
[MC]: PBS (pH 7.0, containing
0.1 M KCl)
[L]: 0.001 to 100 ng/mL for
both [LgS]
[DL]: 0.5 and 0.8 pg/mL for
CEA and AFP
[S]: 11.19, 27.866 µA/(ng/mL),
for CEA and AFP
[SL]: 10 days
[CR]: 0.9985, 0.9957 for CEA
and AFP
[76]
[DP]: CGN-Thi-anti-CEA,
CGN-DAP-anti-PSA and
CGN-Cd2+-anti-AFP
[Anal]: PSA, CEA, AFP
[DM]: DAP, Thi, Cd2+
[Tran]: SWV −1.2 V to 0.2 V (vs.
SCE) [PA] 50 mV [PW] 50 ms to
record Thi, DAP and Cd2+ at
−0.05 V, −0.35 V and −0.65 V
[IC]: (i) PSA/CEA/AFP conc
35 min, 37 ◦C, (ii) [DP] 45 min,
37 ◦C,
[MC]: PBS (pH 6.5, 0.1 M)
[L]: 0.01–100 ng/mL for all
three [LgS]
[DL]: 4.8, 2.7 and 3.1 pg/mL
for PSA, CEA and AFP
[S]: 4.12, 5.84,
5.48 µA/(ng/mL), for PSA,
CEA and AFP
[SL]: 2 weeks
[CR]: 0.997, 0.995, 0.997 for
PSA, CEA and AFP
[75]
[DP]: M-Pt-anti-CA125,
M-Pt-anti-CA153,
M-Pt-anti-CEA
[Anal]: CEA, CA153, CA125
[Tran]: DPV in −0.65 to 0.4 V
[IC]: (i) CEA, CA153, CA125 conc
1 h, RT, (ii) [DP] 1 h, RT
[MC]: PBS (pH 7.4) containing
5 mM H2O2
[L]: 0.02–20 ng/mL,
0.008–24 U/mL,
0.05–20 U/mL for CEA,
CA153 and CA125, [LgS]
[DL]: 7.0 pg/mL, 0.001 U/mL
and 0.002 U/mL, for CEA,
CA153 and CA125
[SL]: one month
[CR]: 0.9927, 0.9962, 0.9988 for
CEA, CA153 and CA125
[30]
[DP]: anti-CA72-4/PANi–Au
AMNPs
[Anal]: CA72-4
[DM]: H2O2
[Tran]: amperometric at −0.4 V
[IC]: (i) CA72-4 conc 1 h, RT, (ii)
[DP] 1 h, RT
[MC]: PBS pH 7.4 with
5.0 mmol/L H2O2
[L]: 2 to 200 U/mL [LS]
[DL]: 0.10 U/mL
[S]: 0.814 µA/(U/ml)
[SL]: 20 days
[CR]: 0.9945
[55]
[DP]:
Fe3O4@SiO2–Fc–anti-CEA/HRP
[Anal]: CEA
[DM]: Fc
[Tran]: DPV in −0.1 to 0.8 V
[IC]: (i) CEA conc 40 min, RT, (ii)
[DP]
[MC]: PBS (pH 7.4) with 4 mM
H2O2
[L]: 0.001 to 80 ng/mL [LS]
[DL]: 0.0002 ng/mL
[S]: 0.3867 µA/(ng/mL)
[SL]: 3 weeks
[CR]: 0.99
[35]
[DP]: anti-SCCA/Pd–Au/C
[Anal]: SCCA
[DM]: H2O2
[Tran]: amperometric at −0.2 V
[IC]: (i) SCCA conc, (ii) [DP] 1 h
[MC]: PBS pH 6.8 with H2O2
[L]: 0.005 to 2 ng/mL [LS]
[DL]: 1.7 pg/mL
[S]: 4.351 µA/(ng/mL)
[SL]: 7 days
[CR]: 0.9995
[28]
[DP]:
Cu@Ag-CD-ADA-anti-CEA
[Anal]: CEA
[DM]: H2O2
[Tran]: amperometric at −0.4 V
[IC]: (i) CEA conc, 60 min, RT, (ii)
[DP] 60 min, RT
[MC]: PBS pH 7.0 with
5 mM H2O2
[L]: 0.0001–20 ng/mL [LS]
[DL]: 20 fg/mL
[S]: (i) 212.46 µA/(ng/mL)
below 0.5 ng/mL, (ii)
5.82 µA/(ng/mL) above
0.5 ng/mL
[SL]: 1 week
[CR]: (i) 0.9955, (ii) 0.9982
[37]
[DP]: anti-AFP/Fe3O4@C@Pd
[Anal]: AFP
[DM]: H2O2
[Tran]: amperometric at −0.4 V
[IC]: (i) AFP conc, 1 h, (ii) [DP]
[MC]: PBS pH 6.5 with
5 mM H2O2
[L]: 0.5 pg/mL to 10 ng/mL
[LgS]
[DL]: 0.16 pg/mL
[S]: 45.195 µA/(ng/mL)
[SL]: 30 days
[CR]: 0.981
[33]
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[DP]: anti-CEA/NP-PtFe
[Anal]: CA15-3
[DM]: H2O2
[Tran]: chronoamperometry at
−0.4V
[IC]: (i) CA15-3 conc, 1 h, RT, (ii)
[DP] 1 h, RT
[MC]: PBS pH 7.4 with
5 mM H2O2
[L]: 0.002 to 40 U/mL [LS]
[DL]: 3 × 10−4 U/mL
[S]: 1.879 µA/(U/mL)
[SL]: 10 days
[CR]: 0.9988
[31]
[DP]:
anti-AFP/PdNi/N-GNRs
[Anal]: AFP
[DM]: H2O2
[Tran]: DPV
[IC]: (i) AFP conc, 1 h, RT, (ii) [DP]
1 h, RT
[MC]: PBS pH 7.0 with
5 mM H2O2
[L]: 0.0001–16 ng/mL [LS]
[DL]: 0.03 pg/mL
[S]: (i) 161.86 µA/(ng/mL)
below 0.2 ng/mL, (ii)
9.09 µA/(ng/mL) above
0.2 ng/mL
[SL]: 20 days
[CR]: (i) 0.9946, (ii) 0.9969
[39]
[DP]:
Pb2+@Au@MWCNT-Fe3O4
/anti-AFP
[Anal]: AFP
[DM]: H2O2
[Tran]: amperometric at −0.4 V
[IC]: (i) AFP conc, 1 h; RT (ii) [DP]
[MC]: PBS pH 7.4 with
5 mM H2O2
[L]: 10 fg/mL to 100 ng/mL
[LgS]
[DL]: 3.33 fg/mL
[S]: 11.19 µA/(ng/mL)
[SL]: 4 weeks
[CR]: 0.9984
[49]
[DP]: anti-SCCA/Au/Ag/Au
NPs
[Anal]: SCCA
[DM]: H2O2
[Tran]: amperometric at −0.4 V
[IC]: (i) SCCA conc, 1 h, RT, (ii)
[DP] 1 h, RT
[MC]: PBS pH 7.17 with
5 mM H2O2
[L]: 0.5 pg/mL to 40 ng/mL
[LgS]
[DL]: 0.18 pg/mL
[S]: 25.33 µA/(ng/mL)
[SL]: 2 weeks
[CR]: 0.9880
[41]
[DP]: anti-AFP/Pd/
APTES-M-CeO2-GS
[Anal]: AFP
[DM]: H2O2
[Tran]: amperometric at −0.4 V
[IC]: (i) AFP conc, 1 h, 4◦C, (ii)
[DP] 1 h,
[MC]: PBS pH 7.4 with
5 mM H2O2
[L]: 0.1 pg/mL to 50 ng/mL
[LgS]
[DL]: 0.033 pg/mL
[S]: 10.1 µA/(ng/mL)
[SL]: 4 weeks
[CR]: 0.99
[51]
[DP]: anti-SCC/Pt–Fe3O4 NPs
[Anal]: SCC
[DM]: H2O2
[Tran]: amperometric at −0.4 V
[IC]: (i) SCC conc, 1 h, (ii) [DP] 1 h,
[MC]: PBS pH 7.4 with
5 mM H2O2
[L]: 0.05 to 18 ng/mL
[DL]: 15.3 pg/mL
[SL]: 20 days
[65]
[DP]:
anti-CA72-4/PtPd-Fe3O4 NPs
[Anal]: CA72-4
[DM]: H2O2
[Tran]: amperometric at −0.4 V
[IC]: (i) SCC conc, 1 h, 4 ◦C, (ii)
[DP] 1 h,
[MC]: PBS pH 7.0 with
5 mM H2O2
[L]: 0.001–10 U/mL
[DL]: 0.0003 U/mL
[SL]: 10 days
[67]
[DP]:
CNTs/PDDA/HRP/ConA/
HRP-anti-CEA
[Anal]: CEA
[DM]: hydroquinone
[Tran]: DPV in −0.4 to 0.2 V (vs.
SCE) at a scan rate of 50 mV/s
[IC]: (i) CEA conc, 40 min, RT, (ii)
[DP] 60 min, RT
[MC]: PBS (0.02 M, pH 7.5) with 2
mM H2O2 and 3 mM HQ
[L]: (i) 0.05–5 ng/mL and (ii)
5–200 ng/mL, [LS]
[DL]: 0.018 ng/mL
[S]: (i) 1.29 µA/(ng/mL), (ii)
0.0315 µA/(ng/mL)
[SL]: 15 days
[CR]: (i) 0.998, (ii) 0.998
[62]
[DP]:
M-Pd@Pt/NH2-GS/anti-PSA
[Anal]: PSA
[DM]: H2O2
[Tran]: amperometric at −0.4 V
[IC]: (i) PSA conc, 1 h, 4 ◦C, (ii)
[DP] 40 min, RT,
[MC]: PBS pH 7.38 with
5 mM H2O2
[L]: 10 fg/mL–50 ng/mL [LgS]
[DL]: 3.3 fg/mL
[S]: 11.96 µA/(ng/mL),
[SL]: 4 weeks
[CR]: 0.9988
[78]
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[DP]: Ir NPs-anti-CEA
[Anal]: CEA
[DM]: H2O2
[Tran]: amperometric at −0.6 V
[IC]: (i) CEA conc, (ii) [DP] 1 h,
37 ◦C,
[MC]: PBS pH 7.4 with
5 mM H2O2
[L]: 0.5 pg/mL–5 ng/mL [LgS]
[DL]: 0.23 pg/mL
[S]: 0.435 µA/(ng/mL),
[SL]: 30 days
[CR]: 0.99
[79]
[DP]: PBG-Au-anti-CEA;
PPP-Au-anti-NSE; PTBO-Au
anti-CA125;
PMCP-Au-anti-Cyfra21–1; Cd
NCs-Au anti-SCCA
[Anal]: CEA, NSE, CA125,
Cyfra21–1, SCCA
[DM]: PBG-Au, PPP-Au,
PTBO-Au, PMCP-Au and Cd
NCs at 0.4 V, 0.15 V, −0.14 V,
−0.5 V, −0.75 V
[Tran]: SWV in −1.0 V to 0.8 V to
record peaks at 0.4 V, 0.15 V, −0.14
V, −0.5 Vand −0.75 V (vs.
Ag/AgCl) for simultaneously
detection of CEA, NSE, CA125,
Cyfra21–1 and SCCA
[IC]: (i) CEA, SCCA, CA125,
Cyfra21–1 and NSE mix, (ii)
PBG-Au-anti-CEA,
PPP-Au-anti-NSE,
PTBO-Au-anti-CA125,
PMCP-Au-anti-Cyfra21–1, Cd
NCs-Au-anti-SCCA probes
mixture 45 min, 37 ◦C.
[MC]: PB (0.1 M, pH 6.0).
[L]: 0.1 to 100 ng/mL for
SCCA, 1 to 150 ng/mL for
CEA, NSE and Cyfra21–1, and
1 to 150 U/mL for CA125
[LgS]
[DL]: 0.2 ng/mL for CEA,
0.9 ng/mL for NSE, 0.9 U/mL
for CA125, 0.4 ng/mL for
Cyfra21–1 and 0.03 ng/mL for
SCCA
[S]: 3.06 µA/(ng/mL),
4.9 µA/(ng/mL),
3.7 µA/(U/mL),
2.3 µA/(ng/mL),
2.57 µA/(ng/mL), for CEA,
NSE, CA125, Cyfra21–1, SCCA
[SL]: 4 weeks
[CR]: 0.984, 0.983, 0.997, 0.995
and 0.971 for CEA, NSE,
CA125, Cyfra21–1, SCCA
[80]
[DP]: HRP-MNP-anti-PSA,
HRP-MNP-anti-PSMA,
HRP-MNP-anti-IL-6,
HRP-MNP-anti-PF-4
[Anal]: PSA, PSMA, IL-6, PF-4
[DM]: HQ
[Tran]: DPV from 0.0 V to −0.4 V
vs. Ag/AgCl at 4 mV step, 25 mV
amplitude, and 0.5 s pulse and 15
Hz
[IC]: (i) [Anal]: mix with [DP], (ii)
incubation with sensor
[MC]: PBS with 1 mM HQ and
100 µM H2O2
[L]: 2 pg/mL to 200 ng/mL for
PSA, 0.05 pg/mL to 5 ng/mL
for IL-6, 0.1 pg/mL to
10 pg/mL for PF-4, and
0.15 pg/mL to 15 ng/mL for
PSMA [LgS]
[S]: 0.84 ± 0.06 nA/(pg/mL),
for PSA, 0.90 ± 0.09
nA/(pg/mL), for IL-6, 0.98 ±
0.07 nA/(pg/mL), for PF-4,
and 1.1 ± 0.1 nA/(pg/mL), for
PSMA
[SL]: 7 days
[81]
[DP]: AuNP-HRP, anti-PSA
[Anal]: PSA
[DM]: TMB
[Tran]: amperometric at −0.1 V
[IC]: (i) PSA conc 250 µL at
30 µL/min flow, (ii) [DP]
[MC]: PBS pH 7.4 with TMB-H2O2
[L]: 0.2–12.5 ng/mL [LS]
[DL]: 0.2 ng/mL
[S]: 2.24 nA/(ng/mL)
[CR]: 0.94
[82]
[DP]: Primer-AuNP-PSA
aptamer
[Anal]: PSA
[DM]: CuNPs
[Tran]: DPSV in −0.2 to 0.6 V with
4 mV step, amplitude 0.05 V, [PW]:
0.05 s, pulse period 0.5 s,
deposition potential −0.5 V,
deposition time 300 s
[IC]: (i) PSA conc, 1 h, 37 ◦C, (ii)
[DP] 1 h, 37 ◦C, (iii) RCA reaction,
(iv) CuNP formation, 30 min, RT
[MC]: Cu2+ in 0.5 M HNO3
[L]: 0.05–500 fg/mL [LgS]
[DL]: 0.02 fg/mL
[S]: 3.48 µA/(fg/mL)
[CR]: 0.995
[83]
[DP]:
anti-CYFRA-1-HRP/AuNPs/
Thi/MWCNT-NH2
[Anal]: CYFRA-1
[DM]: Thi
[Tran]: DPV in −0.4 to 0 V
[IC]: (i) CYFRA-1 conc for 1 h,
35 ◦C (ii) [DP] for 1 h, 35 ◦C
[MC]: 2 mM H2O2
[L]: 0.1–150 ng/mL [LS]
[DL]: 43 pg/mL
[S]: 0.446 µA/(ng/mL)
[SL]: 15 days
[CR]: 0.9937
[84]
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[DP]:
anti-AFP-Co3O4@MnO2-Thi
[Anal]: AFP
[DM]: Thi
[Tran]: DPV in −0.6 to 0.6 V
[IC]: (i) AFP conc, (ii) [DP]
[MC]: dried 10 µL unbound [DP]
on AgNP/SPEC using 50 µL PBS
[L]: 0.001–100 ng/mL [LgS]
[DL]: 0.33 pg/mL
[S]: 5.24 µA/(ng/mL)
[CR]: 0.9977
[85]
[DP]: antiHER2/
Hyd@AuNP-APTMS-Fe3O4
[Anal]: HER2
[DM]: AgNPs
[Tran]: DPV in 0 to 0.6 V
[IC]: (i) HER2 conc for 30 min,
37 ◦C, (ii) [DP] 30 min, 37 ◦C,
0.01 M AgNO3, 25 min
[MC]: 0.01 M AgNO3, 25 min
[L]: 5 × 10−4 to 50.0 ng/mL
[LgS]
[DL]: 2.0 × 10−5 ng/mL
[S]: 1.9194 µA/(ng/mL)
[CR]: 0.9906
[86]
[DP]: anti-CEA-AuNP-Fc
[Anal]: CEA
[DM]: Fc
[Tran]: SWV in 0 to 0.6 V
[IC]: (i) CEA conc for 45 min, (ii)
[DP] for 45 min
[MC]: 0.1 M PBS (pH~7.0)
[L]: 0.5 to 10 ng/mL [LS]
[DL]: 0.2 ng/mL
[S]: 0.4494 µA/(ng/mL)
[SL]: 3 weeks
[CR]: 0.9968
[87]
[DP]: anti-PSA-HRP
[Anal]: PSA
[DM]: MB
[Tran]: SWV in −0.4 to 0.15 V
[IC]: (i) PSA conc for 25 min, (ii)
[DP] for 30 min,
[MC]: 1 mM MB + 2.5 mM H2O2
[L]: 1–18 ng/mL [LS]
[DL]: 1 pg/mL
[S]: 3.234 µA/(ng/mL)
[SL]: 3 weeks
[CR]: 0.996
[88]
[DP]:
HRP-anti-CEA-AuNP-TiO2-GR
[Anal]: CEA
[DM]: HQ
[Tran]: DPV in 0.55 to −0.3 V
[IC]: (i) CEA conc for 30 min, (ii)
[DP] for 1 h, 35 ◦C
[MC]: 2 mM H2O2 + 2.5 mM HQ
[L]: 0.005–200 ng/mL [LgS]
[DL]: 3.33 pg/mL
[S]: 11.98 µA/(ng/mL)
[SL]: 15 days
[CR]: 0.994
[89]
[DP]:
PtCu@rGO/g-C3N4/anti-PSA
[Anal]: PSA
[DM]: Thi
[Tran]: amperometric −0.4 V
[IC]: (i) PSA conc for 30 min, (ii)
[DP] for 50 min, RT
[MC]: 5 mM H2O2
[L]: 50 fg/mL to 40 ng/mL
[LgS]
[DL]: 16.6 fg/mL
[S]: 15.97 µA/(ng/mL)
[SL]: 4 weeks
[CR]: 0.9913
[90]
[DP]:
M-Pd@Pt/NH2-GS/anti-PSA
[Anal]: PSA
[DM]: H2O2
[Tran]: amperometric −0.4 V
[IC]: (i) PSA conc for 1 h, 4◦C, (ii)
[DP] for 40 min, RT
[MC]: 5 mM H2O2
[L]: 10 fg/mL to 50 ng/mL
[LgS]
[DL]: 3.3 fg/mL
[S]: 11.96 µA/(ng/mL)
[SL]: 4 weeks
[CR]: 0.9988
[78]
[DP]: anti-AFP-Pt
NPs/Co3O4/graphene
[Anal]: AFP
[DM]: H2O2
[Tran]: amperometric −0.4 V
[IC]: (i) AFP conc for 1 h, 4 ◦C, (ii)
[DP] for 1 h, 4 ◦C
[MC]: 5 mM H2O2
[L]: 0.1 pg m/L to 60 ng/mL
[LgS]
[DL]: 0.029 pg/mL
[S]: 9.71 µA/(ng/mL)
[SL]: 28 days
[CR]: 0.996
[91]
[DP]: GS-Fe3O4/Au@Ag/
Ni2+-anti-CEA
[Anal]: CEA
[DM]: H2O2
[Tran]: amperometric −0.4 V
[IC]: (i) CEA conc for 1 h, RT, (ii)
[DP] for 1 h, RT
[MC]: 5 mM H2O2
[L]: 0.1 pg/mL to 100 ng/mL
[LgS]
[DL]: 0.0697 pg/mL
[S]: 6.62 µA/(ng/mL)
[SL]: 2 weeks
[CR]: 0.998
[92]
[DP]: HRP-anti-CEA
[Anal]: CEA
[DM]: Thi
[Tran]: DPV in −0.4 to 0.1V
[IC]: (i) CEA conc + [DP] for
30 min, RT
[MC]: 0.5 mM Thi + 5 mM H2O2in
PBS
[L]: 0.02 to 12 ng/mL [LS]
[DL]: 0.01 ng/mL
[SL]: 4 weeks
[CR]: 0.998
[94]
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[DP]: PdCu-anti-CEA
[Anal]: CEA
[DM]: polyaniline
[Tran]: DPV in −0.2 to 0.6 V
[IC]: (i) CEA conc for 1 h, (ii) [DP]
RT
[MC]: aniline polymerization by
CV in −1 to 1 V, 200 s, 100 mV/s
[L]: 0.1 pg/mL to 10.0 ng/mL
[LgS]
[DL]: 0.08 pg/mL
[S]: 2.49 µA/(ng/mL)
[SL]: 5 weeks
[CR]: 0.99
[95]
[DP]: anti-AFP-GNPs-HRP
[Anal]: AFP
[DM]: HQ
[Tran]: amperometric −0.2 V
[IC]: (i) AFP conc + [DP] for
20 min, RT
[MC]: 2mM HQ + 2 mM H2O2
[L]: 20 to 100 ng/mL [LS]
[DL]: 0.64 ng/mL
[S]: 0.3869 µA/(ng/mL)
[SL]: 15 days
[CR]: 0.9940
[96]
[DP]: streptavidin-HRP
[Anal]: HER2
[DM]: TMB
[Tran]: CV in −0.2 to 0.8 V,
50 mV/s
[IC]: (i) HER2 conc for 2 h, RT and
dried, (ii) [DP] for 2 h, RT and
dried, (iii) streptavidin-HRP
30 min, RT, (iv) TMB-H2O2 20 min
[L]: 5 to 20 ng/mL and 20 to
200 ng/mL [LS]
[DL]: 4 ng/mL and 5 ng/mL
[S]: 0.087 µA/(ng/mL) and
0.28 µA/(ng/mL)
[SL]: 7 days
[109]
[DP]:
anti-AFP/HRP-Au@ZnO
[Anal]: AFP
[DM]: TMB
[Tran]: DPV in −0.1 to 0.6 V
[IC]: (i) AFP conc for 40 min,
37 ◦C, (ii) [DP]
[MC]: 0.1 mM TMB + 0.2 mM
H2O2
[L]: 0.02 pg/mL to 10ng/mL
and 10 to 100 ng/mL [LgS]
[DL]: 0.01 pg/mL
[S]: 1.48 µA/(10−10 g/mL)
and 6.15 µA/(10−10 g/mL)
[SL]: 1 week
[CR]: 0.9956 and 0.9917
[97]
[DP]: anti-PSA/AuNPs
[Anal]: PSA
[DM]: Ag (I) ions
[Tran]: Linear sweep anodic
striping in −0.2 to 0.5 V, 50 mV/s
[IC]: (i) PSA conc for 30 min, RT,
(ii) [DP] for 40 min, RT, (iii) 1st Au
enhancement, (iv) spiky gold
enhancement, (v) silver
enhancement
[MC]: 1 M KCl
[L]: 1.95 to 125 pg/mL and
0.125 to 10 ng/mL [LS]
[DL]: 1.2 pg/mL
[S]: 17.51 µA/(ng/mL) and
3.5 µA/(ng/mL)
[CR]: 0.99 and 0.9896
[98]
[DP]:
Co3O4@CeO2-Au@Pt-anti-SCCA
[Anal]: SCCA
[DM]: H2O2
[Tran]: amperometric −0.4 V
[IC]: (i) SCCA conc for 1 h, (ii)
[DP] for 1 h
[MC]: 5 mM H2O2
[L]: 100 fg/mL to 80 ng/mL
[LgS]
[DL]: 33 fg/mL
[S]: 4.43 µA/(ng/mL)
[SL]: 4 weeks
[CR]: 0.998
[99]
[DP]: Au@Ag/PDA-PR-MCS
[Anal]: AFP
[DM]: H2O2
[Tran]: amperometric −0.4 V
[IC]: (i) AFP conc for 30 min, (ii)
[DP] for 1 h
[MC]: 5 mM H2O2, 30 min
[L]: 20fg/mL to 100 ng/mL
[LgS]
[DL]: 6.7 fg/mL
[S]: 16.07 µA/(ng/mL)
[SL]: 1 month
[CR]: 0.9987
[100]
[DP]:
MSN-MB/PDA-anti-PSA
[Anal]: PSA
[DM]: MB
[Tran]: SWV −0.7 to 0.3 V
[IC]: (i) PSA conc for 50 min,
37 ◦C, (ii) [DP] for 1 h, 37 ◦C
[MC]: 0.1 M HCl, 40 ◦C, 15 min
[L]: 10 fg/mL to 100 ng/mL
[LgS]
[DL]: 1.25 fg/mL
[S]: 18.84 µA/(ng/mL)
[SL]: 30 days
[CR]: 0.992
[101]
[DP]: AuPd NCNs-anti-CA
15-3
[Anal]: CA 15-3
[DM]: H2O2
[Tran]: amperometric 0.2 V
[IC]: (i) CA 15-3 conc. drop and
dried 4 ◦C, (ii) [DP] incubation
[MC]: 5 mM H2O2
[L]: 0.001 pg/mL to
100 ng/mL [LgS]
[DL]: 0.35 fg/mL
[S]: 14.29 µA/(ng/mL)
[SL]: 7 days
[CR]: 0.9954
[102]
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[DP]: Au@Pt
DNa/NG/Cu2+-anti-CEA
[Anal]: CEA
[DM]: H2O2
[Tran]: amperometric −0.4 V
[IC]: (i) CEA conc, (ii) [DP] for
40 min
[MC]: 5 mM H2O2
[L]: 0.5 pg/mL to 50 ng/mL
[LgS]
[DL]: 0.167 pg/mL
[S]: 17.9 µA/(ng/mL)
[SL]: 3 weeks
[CR]: 0.9964
[103]
[DP]: Au@Ag-Cu2O/anti-PSA
[Anal]: PSA
[DM]: 5 mM H2O2
[Tran]: amperometric −0.4 V
[IC]: (i) PSA conc for 1 h, 4 ◦C, (ii)
[DP]
[MC]: 5 mM H2O2
[L]: 0.01 pg/mL to 100 ng/mL
[LgS]
[DL]: 0.003 pg/mL
[S]: 4.98 µA/(ng/mL)
[SL]: 16 days
[CR]: 0.9998
[104]
Notes: [Ab2]: detection antibody; [Anal]: analyte; [CR]: correlation coefficient; [DL]: detection limit; [DM]: detection
molecule; [DP]: detection probe; [IC]: incubation conditions; [L]: linearity; [LgS]: log scale; [LS]: linear scale;
[MC]: measurement conditions; [PA]: pulse amplitude; [PP]: pulse period; [PW]: pulse width; [S]: sensitivity;
[SL]: shelf life; [Tran]: transducer. 4-CN: 4-chloro-1-naphthol; Aq: anthraquinone 2-carboxylic acid; ASV:
anodic stripping voltammetry; ASV: square wave anodic stripping voltammetric measurements; Au AMNPs:
Au asymmetric multicomponent nanoparticles; CA 19-9: carbohydrate antigen 19-9; CA15-3: carbohydrate
antigen 15-3; CA72-4: carbohydrate antigen 72-4; Cd NCs-Au: Cd nanocubes-gold; CGN: nanocomposite
of carbon and gold; Co: Tris(2,2′-bipyridine-4,4′-di-carboxylicacid)cobalt(III)(Co(bpy)33þ, expressed as; CSV:
cathodic stripping voltammetry; DPSV: differential pulse stripping voltammetry; Fc: ferrocenecarboxylic acid;
MCF: mesoporous carbon form; MCM-41: multifunctional mesoporous silica; M-Pd@Pt: mesoporous core-shell
Pd@Pt; M-Pt NPs: mesoporous platinum nanoparticles; MSNs: mesoporous silica nanoparticles; MUC 1: Mucin 1;
N-GNRs: N-doped graphene nanoribbons; NP-PtFe: nanoporous PtFe; PB: prussian blue; PBG-Au: poly (brilliant
green)-gold; PGN: PtNPs modified graphene nanocomposite; PMCP-Au: poly (m-cresol purple)-gold; PPP-Au: poly
(N-phenyl-p-phenylenediamine)-gold; PTBO-Au: poly (toluidine blue o)-gold; SWCNHs: single-walled carbon
nanohorns; TB: toluidine blue.
3.1. Redox Enzyme Based Detection
The majority of immunosensors till date use redox enzymes for signal amplification and to
enhance sensitivity of the immunoassay [22]. In such assays, the detection molecule, which binds to
the antigen at a second binding site, is either tagged directly to a redox enzyme or is labeled with a tag
capable of binding a modified redox enzyme. After redox enzyme binding, the enzyme catalyzes its
substrate and generate an electroactive product, whose measurement give the information regarding
the target analyte. Redox enzymes are used either as free molecules or after loading them on metallic
or carbon-based nanomaterials for higher signal.
3.1.1. Free Redox Enzyme and Redox Enzyme with Nanomaterial Based Enhancement
In a free redox enzyme and redox enzyme with nanomaterial approach, redox enzyme tagged
with detection antibody catalyzes its substrate to generate the electrochemical response. This section
describes the various approaches investigated by researchers for loading of redox enzymes onto
various nanomaterials for enhancing their concentration during the immunoassay, which in turn
increases the signal response. Among various nanomaterials, gold nanoparticles have been investigated
most. They have also been used in combination with CNTs and other composites. In the last
few years, the use of free enzymes for enhancement strategy is rarely utilized as more advanced
strategies have been developed. In one such study of free enzyme based system, Patris et al. utilized
the horseradish peroxidase (HRP) tagged detection antibody (Ab2) for signal detection in HER2
immunosensor. For signal enhancement, the antibody-antigen complex was incubated with detection
probe for 20 min followed by testing in citrate buffer containing 2.5 mM hydrogen peroxide (H2O2)
and the reduction current for added hydroquinone (HQ) was monitored at −280 mV. Results showed
detection of HER2 at two concentrations: 1 and 200 µg/mL [63]. For better enhancement, researchers
have developed many nanomaterial-tagged redox enzymes based strategies and achieved improved
detection limit and sensitivity. In one such study, Feng et al. utilized physically loaded Ab2 and
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HRP onto AuNPs-PANI@CNTs nanocomposites for signal enhancement in their immunosensor
for CEA detection [47]. Detection probe was developed by chemical reduction of aniline in CNT
presence followed by electrostatic assembly of AuNPs. During immunoassay, Ab1-antigen complex
is incubated with detection probe for 55 min at 37 ◦C and CEA detection down to 0.008 ng/mL
via DPV was achieved in phosphate buffer saline (PBS) containing 4 mM H2O2. They observed
two linear ranges, and ascribed the lower concentration range to isadsorption-controlled processes
on the electrode, whereas linearity in higher concentrations was attributed to diffusion controlled
processes on the electrode. In other study, Kayosi et al. described the use of HRP-prostate specific
antigen (PSA) aptamer-modified AuNP-PAMAM conjugate for signal enhancement [70]. They utilized
glutaraldehyde chemistry for immobilizing PSA aptamer and HRP-PSA aptamer (prepared using
streptavidin-biotin coupling) onto detection probe. With this probe they achieved PSA detection
down to 10 fg/mL when tested by DPV scanning. Figure 3 shows the schematic for detection
probe development. Further, AuNPs have been utilized by Zhang et al. in the development of
AuNPs modified SBA-15 (Au@SBA-15) based detection probe for carbohydrate antigen 19-9 (CA 19-9)
estimation [74]. Ab2-HRP was conjugated onto Au@SBA-15 via Au–NH3+ or Au–SH affinity and
enhanced direct electron transfer (DET) was utilized for signal enhancement. With such probe they
were able to achieve CA 19-9 detection down to 0.01 U/mL.Sensors 2018, 18, x FOR PEER REVIEW  29 of 44 
 
 
Figure 3. Illustration of the stepwise process for PSA immunosensor fabrication. Reproduced with 
permission from [70]. 
The use of HRP modified hollow AuNPs has been described by Li et al. for the development of 
an AFP immunosensor. In their method, hollow AuNPs were synthesized by HAuCl4 reduction in 
N2 environment using sodium borohydride (NaBH4), sodium citrate and CoCl2·6H2O mixed solution 
and then modified with L-cysteine modified HRP-NPs. Physically immobilized Thi-anti-AFP based 
probe then achieved AFP detection down to 8.3 pg/mL when incubated with Ab1-antigen for 30 min 
at room temperature and the DPV signal was recorded in the presence of H2O2 [40]. Figure 4 shows 
the schematic for HRP-HRP-NPs-hollow AuNPs-Thi@anti-AFP bioconjugates development. Moving 
away from gold, Wang et al. described the use of Fe3O4 and HRP modified mesoporous silica 
nanoparticles (MSNs) based detection probe for an AFP immunosensor. The detection probe with 
Ab2 and HRP were immobilized using glutaraldehyde chemistry, and showed AFP detection down 
to 4 pg/mL when tested via CV in PBS with and without 5 mmol/L H2O2 [64]. In another study, 
Wang et al. described silver nanoparticles (AgNPs) based detection probe for CEA estimation. For 
probe development anti-CEA and glucose oxidase (GOD) were physically immobilized onto Ag 
nanospheres prepared via an ethylene glycol (EG) and poly(vinyl pyrrolidone) (PVP) assisted 
method. For immunoassay, probe was incubated with Ab1-antigen for 1 h at 4 °C and the resulting 
complex was tested via DPV. With such probe they achieved CEA detection down to 0.27 pg/mL [56]. 
Further, Zhou et al. utilized HRP tagged BSA-nanosilver microspheres (Ag@BSA) to quantify CEA. 
Using enzymatic precipitation and amplification of tyramine signal, they achieved CEA detection 
down to 5.0 pg/mL via DPV method [108]. Tang et al. utilized HRP and Ab2 modified magnetic 
nanoparticles (MNPs) based strategy for PSA, PSMA, IL-6, and PF-4 estimation in ab array format. 
HRP and Ab2 were tagged onto MNP via biotin–streptavidin chemistry. Using HRP tag and added 
HQ as mediator they detected the target via DPV in the presence of H2O2 and achieved detection 
down to pg/mL range for all four analytes [81]. In other study, Uludag et al. utilized HRP and 
anti-PSA tagged AuNPs as detection probe TMB as mediator to achieve detection down to 0.2 ng/mL 
when tested via amperometric at −0.1 V in the presence of H2O2 [82]. 
Figure 3. Illustration of the stepwise process for PSA immunosensor fabrication. Reproduced with
permission from [70].
The use of HRP modified hollow AuNPs has been described by Li et al. for the development of
an AFP immunosensor. In their method, hollow AuNPs were synthesized by HAuCl4 reduction in N2
environment using sodium borohydride (NaBH4), sodium citrate and CoCl2·6H2O mixed solution and
then modified with L-cysteine modified HRP-NPs. Physically immobilized Thi-anti-AFP based probe
then achieved AFP detection down to 8.3 pg/mL when incubated with Ab1-antigen for 30 min at
room temperature and the DPV signal was recorded in the presence of H2O2 [40]. Figure 4 shows the
schematic for HRP-HRP-NPs-hollow AuNPs-Thi@anti-AFP bioconjugates development. Moving away
from gold, Wang et al. described the use of Fe3O4 and HRP modified mesoporous silica nanoparticles
(MSNs) based detection probe for an AFP immunosensor. The detection probe with Ab2 and HRP were
immobilized using glutaraldehyde chemistry, and showed AFP detection down to 4 pg/mL when
tested via CV in PBS with and without 5 mmol/L H2O2 [64]. In another study, Wang et al. described
silver nanoparticles (AgNPs) based detection probe for CEA estimation. For probe development
anti-CEA and glucose oxidase (GOD) were physically immobilized onto Ag nanospheres prepared
via an ethylene glycol (EG) and poly(vinyl pyrrolidone) (PVP) assisted method. For immunoassay,
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probe was incubated with Ab1-antigen for 1 h at 4 ◦C and the resulting complex was tested via DPV.
With such probe they achieved CEA detection down to 0.27 pg/mL [56]. Further, Zhou et al. utilized
HRP tagged BSA-nanosilver microspheres (Ag@BSA) to quantify CEA. Using enzymatic precipitation
and amplification of tyramine signal, they achieved CEA detection down to 5.0 pg/mL via DPV
method [108]. Tang et al. utilized HRP and Ab2 modified magnetic nanoparticles (MNPs) based
strategy for PSA, PSMA, IL-6, and PF-4 estimation in ab array format. HRP and Ab2 were tagged onto
MNP via biotin–streptavidin chemistry. Using HRP tag and added HQ as mediator they detected the
target via DPV in the presence of H2O2 and achieved detection down to pg/mL range for all four
analytes [81]. In other study, Uludag et al. utilized HRP and anti-PSA tagged AuNPs as detection
probe TMB as mediator to achieve detection down to 0.2 ng/mL when tested via amperometric at
−0.1 V in the presence of H2O2 [82].Sensors 2018, 18, x FOR PEER REVIEW  30 of 44 
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3.1.2. Redox Enzyme with Carbon Material Based Enhancement
To enhance the response of immunosensors in electrochemical ELISA, various carbon-based
nanomaterials have been explored to increase the loading of redox enzyme tagged detection antibody
probes. This section describes various carbon-based material investigated by researchers to enhance
the sensitivity of immunosensor. Among various carbon-based nanomaterial, graphene oxide and
reduced graphene oxide have gained maximum attention in recent years. Other than graphene,
various carbon-based materials such as CNTs, MWCNTS, nanodots and nanocomposites, etc. have
also been utilized for developing detection probes to achieve high sensitivity. Huang et al. described a
Ag/Au NPs-graphene based enhancement strategy for CEA immunosensor: a 1,5-diaminonaphthalene
(DN)-based Ag/Au–DN–GR probe was prepared simply by mixing Ag/Au (prepared via reduction)
with DN-GR. The immunoassay with physically adsorbed anti-CEA onto Ag/Au–DN–GR showed
CEA detection down to 8 pg/mL when incubated with Ab1-antigen for 40 min [34]. Similarly,
a Au@Pd-GR composite was used by Yang et al. for detection probe development by immobilizing
Thi, HRP and anti-CA19-9. It was observed that synergy between Au@Pd-GR and HRP resulted in
three times higher response in the presence of H2O2 and the sensor exhibited CA19-9 detection down
to 0.006 U/mL [72].
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GR-PAMAM dendrimer conjugate based detection probe development was described by
Shen et al. GR and PAMAM were conjugated via EDC/NHS chemistry and then utilized for anti-AFP
and HRP binding using glutaraldehyde cross-linking. With this simple probe and hydroquinone as
detection molecule, they achieved amperometric detection of AFP down to 0.45 ng/mL [50]. In other
study, Yang et al. described the development of duel enzyme bio-catalyzed precipitation of 4-CN
based immunosensor for α-fetoprotein (AFP) detection. For probe, HRP, GOD and anti-AFP were
immobilized via EDC/NHS chemistry on carboxylated SWCNHs. With their probe they achieved AFP
detection down to 0.33 pg/mL [73].
3.2. Redox Marker Based Detection
Other than redox enzymes, researchers have employed the use of redox active tags such as
nanoparticles, quantum dots or organic/inorganic molecules for measuring signal from sandwich
immunoassay. Such molecules are also either tagged directly to detection molecule in free form
or after loading to other nanomaterials. Such tags on electrochemical oxidation/reduction provide
the information of tags concentration which in turn can be related to the analyte concentration in
the immunoassay.
3.2.1. Free Redox Marker and Redox Marker with Metallic Nanomaterial Based Enhancement
This section describes various different types of redox markers either in free form or loaded onto
nanomaterials, investigated by researchers to enhance the sensitivity of sandwich-based immunoassays.
The higher the presence of redox markers suggests higher responses, thus loading of such markers
onto nanomaterials has shown promise in enhancing the sensitivity of immunoassays. Among various
nanomaterials, AuNPs have gained maximum attention for achieving higher loading of redox tags.
Yang et al. described the use of 6-ferrocenyl hexanethiol tagged AuNPs based probe development for
PSA detection. With high physical loading of anti-PSA onto Fc tagged AuNPs, they were able to detect
PSA down to 5.4 pg/mL [68]. Lin et al. introduced the use of AuNPs-mesoporous carbon form (MCF) as
redox tag. In immunoassay physically tagged anti-CEA on Au/MCF was incubated with Ab1-antigen
for 40 min and attached Au/MCF tags were then utilized for silver-deposition by incubating with
enhancer solutions in dark for 4 min at 37 ◦C. Results of CEA detection using anodic stripping analysis
revealed detection down to 0.024 pg/mL [71]. Chitosan-AuNP based detection probe was described by
Chen and Ma. They utilized CHIT-PB-AuNP and CHIT-FC-AuNP probes for CEA and AFP detection,
respectively. Corresponding Ab2 were physically immobilized on desired conjugate and used for
immunoassay. For measurement, detection probe mixture was incubated with Ab1-antigen for 45 min
at 37 ◦C and DPV signal was recorded in PBS. With this scheme, they were able to detect AFP and
CEA down to 0.03 ng/mL and 0.02 ng/mL, respectively [52]. In another study, Feng et al. described
the development of anti-AFP2,2-AuNPs-Thi@rGO and anti-CEA2,1-AuNPs-PB@rGO bioconjugates as
detection probe. Probes were easily prepared by mixing and physical adsorption. For measurement,
detection probes with physically adsorbed Ab2 were incubated with Ab1-antigen for 50 min at 37 ◦C
and DPV measurements were carried out in PBS. Results indicate that with their probes, CEA and
AFP can be estimated simultaneously down to 0.12 ng/mL and 0.08 ng/mL, respectively [36]. Figure 5
shows the preparation process of immunosensing probes. Further, Liu and Ma described PB–CS-Au
and Cd–CS-Au based immunoprobes for CEA and AFP detection. With physically adsorbed Ab2,
they were able to detect CEA and AFP simultaneously down to 0.006 ng/mL for AFP and 0.01 ng/mL
for CEA [44]. Cd2+ modified nanoporous TiO2 has also been utilized for probe development for
carbohydrate antigen 15-3 (CA15-3) detection down to 0.008 U/mL [32].
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pre-synthesized AuNPs onto Thi/rGO or PDDA modified PB/rGO. The bound AuNPs were then 
utilized for physical adsorption of desired antibodies. Reproduced with permission from [36]. 
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Figure 5. Preparation process of immunosensing probes. In brief, reduced GO was first treated
with Thi/Pb for their electrostatic binding, which was then utilized for physical adsorption of
pre-synthesized AuNPs onto Thi/rGO or PDDA modified PB/rGO. The bound AuNPs were then
utilized for physical adsorption of desired antibodies. Reproduced with permission from [36].
In a different strategy, polymer-nanotags based signal probes were described by Wang et al.
for AFP and CEA detection. Probes were prepared by mixing metal ions (Cd2+, Pb2+) modified
Apo solution with PLL-Au nanocomposites, which was then utilized for physical adsorption of Ab2.
For detection via SWV, they utilized captured metal ions during immunoassay to deposit bismuth film
at −1.2 V and estimated AFP and CEA at −0.78 V and −0.53 V, simultaneously. With this scheme they
achieved detection down to 4 pg/mL for both targets [59]. Figure 6 shows the preparation process of
immunosensing probes. Wang et al. also described the use of PtPNPs-Cd2+ and PtPNPs-Cu2+ hybrids
based detection probes for immunosensing. Cd2+ or Cu2+ ions modified PTPNPs were utilized for
physical immobilization of Ab2 and DPV signals were recorded for CEA and AFP at −0.736 V and
0.004 V, respectively. Using these probes and incubation for 1 h at 37 ◦C with Ab1-antigen conjugate,
they achieved detection down to 0.002 ng/mL and 0.05 ng/mL for CEA and AFP, respectively [29].
Similarly, Wang et al. described the use of nanocubes of copper and cadmium hexacyanocobaltate
based probes for CEA and AFP immunosensing and achieved detection down to 0.0175 ng/mL and
0.0109 ng/mL for CEA and AFP respectively [53].
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Use of AuNPs modified mesoporous carbon CMK-3 has been described by Wu et al. to
develop detection probes for CEA and SCCA estimation, simultaneously. For detection probe
Au@CMK-3-anti-CEA-neutral red and Au@CMK-3-anti-SCCA-thionine conjugate were prepared
via EDC/NHS chemistry and assay results using these probes showed detection down to 0.013 ng/mL
and 0.010 ng/mL for CEA and SCCA, respectively [66]. Cu2+ and Pb2+ tagged AuNPs have also been
used by Xu et al. for CEA and AFP detection down to 4.6 pg/mL and 3.1 pg/mL, respectively [54].
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In other approach, Wang et al. described AuNPs modified mesoporous silica KIT-6 (Au@KIT-6) as
surface to bind Ab2 (anti-CEA) and toluidine blue (TB) mediator based strategy for immunosensor
development for CEA detection. With the developed probe (TB/Au@KIT-6/CMC/ILs-Ab2), they
incubated Ab1-antigen complex for 1 h and achieved detection of CEA down to 3.3 fg/mL [45].
Figure 7 shows the preparation process of the immunosensing probes. Furthermore, they have shown
that AuNPs modified multifunctional mesoporous silica (MCM-41) can be employed for detection
probe development by immobilizing Ab2 and TB. Using such approach they detected AFP down to
0.05 pg/mL [57]. Metal alginate nanobeads (M-Alg), with different metals attached to specific detection
antibodies can be employed for simultaneous estimation of biomarkers such as AFP, CEA and PSA [43].
Similarly Metal-Envision copolymer has also been utilized for detection probe preparation to achieve
enhanced detection of Ca19-9, AFP and CEA [107].
Zhu et al. described the use of a hybridization chain reaction-based approach for testing four
biomarkers simultaneously. For detection probe development, biotin-Ab2 was mixed with gold
magnetic particles (Au/Sio2-Fe3O4). The conjugate was then treated in sequence with streptavidin
bio-S1, bio-S2 and bio-S3 for bio-dsDNA/SA/bio-Ab2/Au/SiO2-Fe3O4 development via HCR reaction.
Product was then modified with redox tag-streptavidin to obtain the detection probe. With such a probe
they were able to detect AFP, CEA, CA125 and PSA down to 62, 48, 77 and 60 fg/mL, respectively [46].Sensors 2018, 18, x FOR PEER REVIEW  33 of 44 
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A quadruple signal amplification strategy has been described by Zhou et al. for CEA detection.
In amplification strategy streptavidin-labeled gold nanoparticles (AuNP-SA) were utilized for
immobilizing detection antibody (Ab2) and initiator DNA strands (s0) using avidin-biotin coupling.
For amplified electrochemical signal measurement, CEA sandwiched between Ab1 immobilized on
sensor surface and modified Ab2 underwent hybridization with s1 and s2 DNA strands to form a
concatamer followed by interaction with hemin, which resulted in formation of DNAzyme capable of
binding with methylene blue. During DPV measurement, reduction of H2O2 by DNAzyme helped in
enhancing methylene signal and sensor for CEA detection exhibited linearity in 1.0 fg/mL to 20 ng/mL
range with detection limit of 0.5 fg/mL [60].
Zhang et al. described the development of a sensing strategy using signal tag of PtNP-
ferrocenedicarboxylic acid based infinite coordination polymer (ICP) in combination with
polyamidoamine dendrimers modified sensor electrode for PSA estimation in a sandwich type
electrochemical ELISA. PtNP@ICP tag enhanced the catalytic reduction of H2O2 during the
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immunoassay to measure PSA. DPV measurements indicated that the sensor is able to detect PSA in
the 0.001 to 60 ng/mL range with detection limit (LOD) of 0.3 pg/mL [61]. Shan and Ma described
the development of a multiple probe by attaching desired Ab2 with specific redox tag and utilized
for simultaneous detection of five biomarkers. Using PBG-Au, PPP-Au, PTBO-Au, PMCP-Au and Cd
NCs-based probes they detected CEA, NSE, CA125, Cyfra21–1 and SCCA simultaneously at 0.4 V,
0.15 V, −0.14 V, −0.5 V and −0.75 V in SWV scans and achieved detection down to 0.2 ng/mL for CEA,
0.9 ng/mL for NSE, 0.9 U/mL for CA125, 0.4 ng/mL for Cyfra21–1 and 0.03 ng/mL for SCCA [80].
Zhu et al. described the use of primer-AuNP-PSA aptamer-based probe with RCA reaction-based
approach for enhanced detection of PSA. During immunoassay captured primer-AuNP-PSA aptamer
was utilized for RCA reaction and CuNP formation in presence of sodium ascorbate and copper
sulphate. Formed CuNPs were then extracted in HNO3 and utilized for sensitive detection of PSA
down to 0.02 fg/mL via DPSV measurements [83].
3.2.2. Redox Marker with Carbon Material Based Enhancement
Other than metallic nanomaterials, carbon materials in various forms such as graphene, CNTs, etc.
have also gained much attention in enhancement strategies for electrochemical ELISA based assays.
These materials provide support to load redox marker and detection antibody for signal enhancement.
This section summarizes various such approaches described by researchers for enhancing the sensitivity
of immunoassays. Using MWCNTs, Chen et al. described a AuNPs/SiO2@MWCNTs-based detection
probe. For detection probe development, COOH-MWCNTs (c-MWCNTs) were first treated with PDDA
to get positively charged MWCNTs, which were then treated with TEOS to make SiO2@MWCNTs.
The obtained SiO2@MWCNTs were again treated with PDDA before incubating in AuNPs solution
for 8 h to obtain a AuNPs/SiO2@MWCNTs nanocomposite. The composite was then incubated with
thionine followed by an aptamer (Apt) solution, where Apt becomes covalently attached to AuNP via
a thiol group. Using this probe, they were able to detect MUC1 down to 1 pM. Figure 8 illustrates the
electrochemical sensing strategy for the detection of MUC 1, with the inset showing the preparation
of Apt/Thi-AuNPs/SiO2@MWCNTs [58]. PtNPs modified graphene nanocomposites (PGN) were
utilized by Jia et al. to develop detection probe for AFP and CEA detection. Using Fc-anti-AFP-PGN or
Thi–anti-CEA-PGN they achieved detection down to 1.64 pg/mL and 1.33 pg/mL for CEA and AFP,
respectively. Figure 9 illustrates the preparation procedure of PGN-Ab1/2 probes [48]. In another study,
Li et al. described 3D graphene sheet (3DGS) prepared from GO reduction using NaI, based detection
probe for CEA and AFP detection. On paper based assay with 3DGS@MB and 3DGS@Fc-COOH
nanocomposites based probes resulted in CEA and AFP detection down to 0.5 and 0.8 pg/mL,
respectively [76].
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Figure 9. Preparation procedure of PGN-Ab1/2 probes: (a) modification with PEI to obtain active
groups of amino; (b) reducing H2PtCl6 to form PtNPs; (c) labeling PGN with thionine-anti-CEA,
ferrocene-anti-AFP, HRP and GOD. Reproduced with permission from [48].
Xu et al. described the development of carbon and gold (CGN) nanocomposite-based
immunoprobes for simultaneous detection of multiple cancer marker. CGN was prepared via
glucose carbonization in the presence of sodium citrate followed by microwave reaction-based
AuNPs deposition from HAuCl4. Further, redox tags were attached using reactive oxygen groups
on CGN via mixing and stirring for 5 h. Physically immobilized antibody-based CGN-Thi-anti-CEA,
CGN-DAP-anti-PSA and CGN-Cd2+-anti-AFP probes showed detection limit of 4.8, 2.7 and 3.1 pg/mL
for PSA, CEA and AFP, respectively. Figure 10 illustrates the electrochemical probe development [75].Sensors 2018, 18, x FOR PEER REVIEW  35 of 44 
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For detection probe, Fe3O4 particles prepared by a solvothermal method were first treated
with TEOS to obtain Fe3O4@SiO2 particles, which were then again treated with APTES to get
Fe3O4@SiO2–NH2. For Fc-COOH and GA binding on prepared particles, Fc-COOH was first
activated using EDC/NHS and then incubated with Fe3O4@SiO2–NH2 and GA overnight with stirring.
Fe3O4@SiO2/Fc/GA precipitates thus obtained were utilized for Ab2 binding by incubation at 4 ◦C
for 2 h. During immunoassay, Fe3O4 of captured probe provide catalytic activity towards H2O2, which
in turn reduce Fc molecules and provide the detection signal. With such approach, they were able to
detect CEA down to 0.0002 ng/mL. Figure 11 illustrates preparation of Fe3O4@SiO2–Fc–Ab2/HRP
bioconjugate [35].
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A polyaniline–Au asymmetric multicomponent nanoparticles (PANI–Au AMNPs)-based strategy
for immunosensor development was described by Fan et al. In their approach, captured PANI–Au
AMNPs exhibited catalytic activity towards added H2O2 and the sensor showed CA72-4 detection
down to 0.10 U/mL. Figure 12 shows the schematic representation of the preparation of the PANI–Au
AMNPs-Ab2 [55]. Gao et al. described the use of Pd-Au/C-based probe for SCCA detection.
During the immunoassay, Pd-Au helped in achieving higher signal from H2O2 during amperometric
measurements and achieved detection down to 1.7 pg/mL [28]. The authors also proposed a
Cu@Ag-CD-based enhancement strategy for immunosensor for CEA. In immunoassay Cu@Ag
in H2O2 presence generated an enhanced signal and achieved detection down to 20 fg/mL [37].
A palladium nanoparticles/carbon-decorated magnetic microspheres-based strategy for development
of immunosensor for AFP was described by Ji et al. In this probe Fe3O4@C@Pd generated an
enhanced signal for H2O2 during amperometric measurement in the assay and achieved detection
down to 0.16 pg/mL [33]. A Pt@CuO-MWCNTs based probe was described by Jiang et al. for
AFP estimation. In presence of H2O2 Pt@CuO-MWCNTs catalyzed the reaction and generated
enhanced signal for AFP detection down to 0.33 pg/mL. Figure 13 shows the preparation procedures
of Pt@CuO-MWCNTs/Ab2 [38].
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Li et al. utilized nanoporous PtFe (NP-PtFe) alloys for probe development and enhanced catalytic
conversion of H2O2 during ampero etric measurement of CA15-3. With NP-PtFe, they achieved
detection down to 3 × 10−4 U/mL when measured in the presence of 5 mM H2O2 at −0.4V [31].
Li et al. describ PdNi/N-GNRs-base probe for H2O2 catalysis. N-GNRs were prepared via
microwave-assisted method and modified with PdNi. D ring assay PdNi enhance catalysis and
helped obtaining a higher signal for AFP detection. With such a probe they achieved detection down
to 0.03 pg/mL when measured in the presence of 5 mM H2O2 [39]. Figure 14 shows the synthetic
process of N-GNRs from N-MWCNTs and the synthetic process of P Ni/N-GNRs. In a other study
Li et al. described the use of Pb2+@Au@MWCNTs-Fe3O4 for enhanced H2O2 catalytic conversion
for AFP detection down to 3.33 fg/mL [49]. Figure 15 illustrates the preparation procedure of
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Au/Ag/Au core/double shell nanoparticles (Au/Ag/Au NPs) as novel enzyme-mimetic labels
for anti-SCCA have been described by Wang et al. The study showed that improved electrocatalytic
activity of Au/Ag/Au NPs for H2O2 reduction resulted in enhanced sensitivity and detection of
SCCA down to 0.18 pg/mL [41]. For AFP estimation, Wei et al. described the use of anti-AFP
tagged GO-CeO2 and Pd nanoparticle-based probes. In such a Pd/APTES-M-CeO2-GS-based
probe, Pd octahedral NPs showed enhanced catalytic activity for H2O2 reduction and the sensor
achieved detection down to 0.033 pg/mL when measured amperometrically at −0.4 V in the presence
of 5 mM H2O2 [51]. Dumbbell shaped Pt–Fe3O4 as labels were described by Wu et al. for SCC
estimation. Results indicate that Pt–Fe3O4 improve H2O2 reduction and the immunosensor achieved
linearity in the 0.05–18 ng/mL range with a detection limit of 15.3 pg/mL [65]. In other study,
Wu et al. described the use of a dumbbell-shaped PtPd-Fe3O4 nanoparticles-based label in designing
immunosensor for CA72-4 biomarker for gastric cancer. Results indicated that PtPd–Fe3O4 improve
H2O2 reduction and immunosensor achieved linearity in the 0.001–10 U/mL range with detection
limit of 0.0003 U/mL [67]. Li et al. described the mesoporous core-shell Pd@Pt nanoparticles loaded by
amino group functionalized graphene (M-Pd@Pt/NH2-GS)-based detection. With such a probe, they
achieved higher reduction of H2O2 to improve the sensitivity of the immunosensor. In immunoassay
for PSA detection they achieved detection down to 3.3 fg/mL [78]. Miao et al. described the use of
PVP-stabilized colloidal iridium nanoparticles, prepared via ethanol reduction-based detection probe.
Physically immobilized anti-CEA was used for detection and Ir NP-based catalyzed reduction of H2O2
helped in achieving amperometric detection of CEA at −0.6 V down to 0.23 pg/mL [79].
Tables 2 and 3 show the details of various strategies used for development of detection probes
for enhanced detection and the various characteristics of the developed immunoassays using
electrochemical ELISA, respectively.
4. Conclusions and Outlook
In the last few years, researchers have shown that electrochemical ELISA-based immunosensors
can achieve similar or even better performance when compared to traditional optical ELISA
immunoassays and are capable of replacing them in the near future. The innovations in nano- and
bio-technologies and in surface and material chemistry have resulted in the development of novel
sandwich assays with improved performance and stability. Further, due to the use of electrochemical
techniques for testing, they have the advantage of providing faster response and on site testing in
either undiluted or treated samples. This review has also described the various approaches which have
been attempted by researchers to develop novel electrochemical immunosensors. It is clear that newer
matrices and immobilization platforms allow higher capturing molecule loading and thus enhanced
signals. Furthermore, the use of carrier materials for detection tags before electrochemical measurement
helps in enhancing the sensitivity of the immunosensors. Although there are many success stories,
Sensors 2018, 18, 2010 39 of 45
there are a few limitations which need further detailed investigation before these electrochemical
ELISA-based sensors can be accepted in clinical practice and able to replace optical ELISA. To improve
the shelf life of the systems and to improve their stability, more detailed research is still required to
understand the nature of biomolecule bound on flat matrices and on nanomaterials. Further, more
studies are required for better surface blocking to prevent non-specific binding, while maintaining
conductivity of sensor surface for higher electrochemical signal and better sensitivity. Moreover, newer
and better packaging approaches are required to be developed to hold all the required chemicals and
reagents required in a multistep ELISA processor, so that the assay can be automated and made less
prone to human errors. It is envisioned that further advancements in nano- and bio-technology along
with chemistry, material science, physics and electronics will pave the way to solve these issues and
result in larger acceptance of these devises in clinical practice.
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